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iABSTRACT
In response to oxidative injury_ murine tumors depend upon the 6SH
oxidation-reduction cycle. The susceptibility of tumor cells to lysis
by a flux of H202, such as generated by granulocytes or activated
macrophages, or by the enzyme glucose oxidase, was augmented by inter­
ference with the 6SH redox cycle. Depletion of tumor cell 6SH was by 2
methods: incubation of cells with buthionine sulfoximine (BSO)_ a
nontoxic inhibitor of GSH synthesis, or with l-chloro-2,4-dinitro­
benzene_ a substrate for 6SH S-transferase. Sensitization to oxidative
cytolysis correlated with 6SH depletion by either method by the critera
of both dose-response and the time course of onset and recovery. A
third approach involved inhibition of glutathione reductase (6R) with
l,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). Here too, interference in
tumor cell GSH metabolism enhanced cytolysis by a flux of H202• In
contrast, inhibition of catalase with aminotriazole had little effect.
This theme was extended into another arena of 6SH metabolism, the
detoxification of reactive electrophiles by the formation of thioether
conjugates with 6SH. The interaction of tumor cell 6SH with four
sesquiterpene lactones (SLs), a class of sulfhydryl-reactive antineo­
plastic agents, was evaluated. SLs are potent depletors of cellular
6SH. Prompt resynthesis of GSH is a critical component of tumor cell
recovery following exposure to SLs. Cytolysis by SLs was augmented by
inhibition of 6SH synthesis with BSO. Potent synergy between BSO and
the SL ve�nolepin was evident even if BSO was not present during but
ii
added just after exposure to vernolepin. For six additional. unrelated
antineoplastics. sulfhydryl reactivity. in terms of their ability to
deplete 6SB. correlated with synergistic lysis in the presence of BSO.
Lysis by BCNU. however. was not enhanced by BSO. in spite of 6SB
depletion.
Vernolepin-mediated cytolysis of P81S cells was dependent upon
exogenous cystine. as was 6SB synthesis. This dependence upon cystine
for cytolysis was not due to a requirement for protein synthesis or 6SB
synthesis. The formation of B202 as a result of cysteine autoxidation
may contribute to the toxicity of vernolepin. In accord with this
hypothesis. inhibition of 6R by BCNU significantly enhanced the
toxicity of vernolepin. Inhibition of catalase by aminotriazole
resulted in less dramatic augmentation of vernolepin-mediated lysis.
iii
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SUMMARY AND DISCUSSION
REFERENCES
INTRODUCTION
Recent developments in our understanding of the process of
oncogenesis at the molecular level. as well as the arising technology
by which human monoclonal antibodies of desired specificity may be
produced in quantity. evoke high expectations for new therapeutic
approaches to neoplastic diseases. Still. we need not rely solely on
the discovery of new drugs or novel treatments. Elucidation of the
biochemistry of antineoplastic action. as well as the defense
mechanisms employed by tumor cells in response to anti-cancer therapy.
can help us to use more effectively the tools we already have. Analysis
of tumor cell defenses could be of use in the design of synergistic
therapeutic combinations and in the analysis of treatment failure.
Much of our pharmacologic armamentarium for the treatment of
infectious and neoplastic diseases has developed from the isolation and
characterization of cell-derived products. presumably of importance in
cell-cell interactions. such as the establishment 9f territorial
niches. Within the mammalian organism. cytotoxicity by cells of the
host immune system is a well studied phenomenon. though identification
of the substances mediating cytotoxicity is still the subject of active
research. Cytolysis of tumor cells by granulocytes and activated
macrophages in certain settings has been shown to proceed by the
secretion of H202• and is thus the result of oxidative injury. It
2can be expected that tumor cell antioxidant defenses are an important
factor in such injury, analysis of which might suggest ways to enhance
both cell-mediated cytotoxicity and alternative oxidant-injury delivery
systems.
In mammalian cells, the glutathione oxidation-reduction cycle
fulfills an important function in antioxidant defense. Our research
group first became interested in tumor cell glutathione metabolism as a
potential determinant of susceptibility to cytolysis by peroxide­
producing leukocytes. This work will be discussed in Section I of
Results. In view of the importance of glutathione for the detoxifica­
tion of reactive electrophiles via thioether conjugate formation, we
next focused on the role of glutathione in lysis of tumor cells by
sulfhydryl-reactive antineoplastic agents. Sections II and III of
Results will describe this topic in detail.
First, I will briefly review some relevant aspects of glutathione
metabolism, followed by a discussion of the various ways in which
glutathione metabolism may be of importance in antineoplastic therapy.
Glutathione (GSB, Fig. 1) has been identified as the predominant
intracellular non-protein sulfhydryl (NPSB) in a wide range of cells,
both prokaryotic and eukaryotic, plant and animal. The now vast
literature concerning the occurence and properties of GSH probably
began with the report by Rey-Pailhade (1888) that a component of
aqueous yeast extracts could reduce sulfur to hydrogen sulfide.
He named this new cell-derived reducing principal "philothion". Twenty­
three years later, across the English Channel, Hopkins (1921) isolated
3eOOH
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Figure 1. Structure of GSH.
4a thiol-containing peptide from a variety of cell types, including
yeast and mammalian liver, which he proposed to be equivalent to
Rey-Pailhade's philothion. Hopkins further demonstrated the existence
of factors within cells capable of catalyzing both the oxidation and
reduction of this peptide, suggesting that such a sulfhydryl-disulfide
redox cycle might be functionally important. At that time, Hopkins
thought philothion was a dipeptide of glutamate and cysteine, and so
renamed it glutathione ("gluta--" for glutamate, "--thi-" for thiol,
and "--one" as in peptone or simple peptide).
A number of monographs and review articles devoted to various
aspects of GSH metabolism and function have been published in the past
decade (Flohe et al. 1974; Meister and Tate 1976; Arias and Jakoby
1976: Kosower and Kosower 1978; Sies and Wendel 1978; Meister et al.
1980). As background for a consideration of the importance of GSB
metabolism in antineoplastic therapy, I will briefly outline some of
this information.
Biosynthesis of GSB occurs in two successive ATP-requiring steps.
First, Y-glutamylcysteine synthetase catalyzes the formation of an
amide linkage between cysteine and the Y-carboxyl of glutamate. GSB
synthetase then mediates the reaction of glycine with the cysteine
carboxyl of y-glutamylcysteine to form the tripeptide Y-glutamyl­
cysteinylglycine.
In mammalian cells, GSH exists in at least three, possibly four,
dynamically interchanging forms. Under normal steady-state conditions,
the majority of GSB exists in the reduced form (0.5-10 mM). Oxidation
of reduced GSB, either non-enzymatically or by the action of
5glutathione peroxidase (GPO), yields glutathione disulfide (GSSG).
NADPH-dependent reduction of GSSG by glutathione reductase (GR), as
well as efflux, effectively maintains the intracellular concentration
of GSSG at very low levels (usually 5-50 �M). The extent to which GSB
oxidation is occuring under normal conditions, that is the flux rate of
GSB through the redox cycle in the absence of an imposed oxidant
stress, has not been determined either in tissue culture or in vivo.
A third form of cellular GSB which has been evaluated in a number
of cell types involves participation of GSB in mixed disulfides with
both protein and non-protein sulfhydryls. In one such study with an
Ehrlich ascites tumor cell line, Modig (1968) found that approximately
35% of total cellular GSB was in disulfide linkage to protein.
Thiol esters of GSB constitute yet another potentially significant
form of cellular GSB. Although the occurence and metabolism of such
thiol esters have not been adequately studied, the identification by
Uotila (1973) of at least three distinct GSB thiol esterases in human
liver is suggestive of functional significance.
The numerous reactions of GSB in mammalian cells can be divided
into those involving principally the y-glutamyl portion of the tri­
peptide, such as the y-glutamyl cycle, versus those of the sulfhydryl
moiety. Sulfhydryl-dependent metabolism of GSB can be further sub­
divided into oxidation-reduction reactions versus nucleophilic
reactions in which the reduced sulfhydryl reacts with an electrophile
to form a thioether (Fig. 2). By forming such thioethers, the cell may
detoxify potentially harmful compounds.
An alternative scheme by which GSB metabolism can be categorized
NADP
glu cys electrophile
'fG�lIY
GS \
GSH
thioether
Figure 2. Aspects of sulfhydryl-dependent GSB metabolism:
oxidation-reduction cycle and thioether formation. The
enzymes shown are: GPO; GRj YGCS. y-glutamylcysteine
synthetase; GS. glutathione synthetase; GST. glutathione
S-transferase.
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7distinguishes between reversible and irreversible loss of reduced GSB.
Reactions involving the formation of GSSG. mixed disulfides. or thiol
esters result in reversible loss since resynthesis of GSB from its
amino acid constituents is not required for maintenance of cellular
content of GSB in the reduced form. In contrast. irreversible loss of
GSB is the consequence of reactions resulting in thiol conjugate
formation. such as the mercapturic acid pathway. or efflux of GSB from
the cell. where it may be degraded by the externally disposed enzyme
y-glutamyl transpeptidase as part of the y-glutamyl cycle. Synthesis is
required for restoration of cellular GSB levels in response to
irreversible loss.
GSB has been shown to playa critical role in cellular defense
against a variety of injurious agents. In this regard. the sulfhydryl
group assumes primary importance. Thus. maintenance of structural and
functional viability in spite of the ongoing production by cells of
reactive oxygen intermediates (ROI). an apparently unavoidable conse­
quence of aerobic metabolism. as well as defense against acute oxidant
injury. relies heavily upon the GSB redox cycle. The capacity of the
redox cycle may be related to the cellular content of GSB. GR. and/or
GPO. as well as to the ability of the cell to regenerate NADPH via the
pentose phosphate shunt. Similarly. as the non-protein sulfhydryl of
greatest abundance. GSB protects against toxic electrophiles by thio­
ether formation. The effectiveness of this pathway may depend upon the
intracellular concentration of GSB. the presence of GSB S-transferases
of appropriate specificity. and/or the capacity of the cell for rapid
resynthesis of GSB.
8The importance of GSH-mediated detoxification in the pharmacology
and toxicology of various agents has been discussed recently in a
number of reviews (Mitchell et al. 1976; Jakoby 1978; Orrenius and
Jones 1978; Reed and Beatty 1980). However� a comprehensive evaluation
of the implications of GSH metabolism within the context of therapeutic
intervention in disease states has not been provided.
The rest of this introduction will focus on a consideration of the
various ways in which GSH metabolism may be of importance in anti­
neoplastic therapy. I will begin by outlining four major determinants
of therapeutic efficacy in which GSH metabolism may be involved.
A. Detoxification. GSH may mediate protection via detoxification
of the active species and/or repair of the injury once
incurred.
B. Toxification. GSH may be involved in formation of the active
species� either within the tumor target or normal cells
of the host.
c. Delivery. Drug targetting� drug uptake� and other aspects
concerning delivery of the toxic agent to its site of
action may be influenced by GSH metabolism.
D. Therapeutic Interactions. An alteration in the GSH status of
tumor or host as a result of a particular therapeutic
intervention may influence the effectiveness or toxicity of
9a concurrent therapy.
For each of the above categories, specific examples of antineo­
plastic inverventions will be discussed. In this regard, it will be
important to distinguish between GSH metabolism of tumor and host.
A. Detoxification.
1. Radiation. The attenuated radiosensitivity of cells in an
oxygen-deficient atmosphere compared to irradiation in air has been
termed the "oxygen effect". Neither nucleic acids nor enzymes in
aqueous suspension exhibit such an effect. Working with T2 bacterio­
phage, Howard-Flanders (1960) showed its sensitivity to inactivation by
irradiation to be independent of the concentration of oxygen. The
addition of cysteamine, however, decreased the extent of inactivation
when irradiation was conducted in a nitrogen atmosphere, while having
no effect in the presence of oxygen. Similar studies concerning
inactivation of DNA and trypsin by irradiation in the presence and
absence of GSB helped to focus attention on cellular thiols as
mediators of the oxygen effect (Hutchinson 1961).
The notion that cellular NPSH might be responsible for anoxic
radioresistance has been evaluated in a variety of settings. Revesz et
al. (1963) studied a sub-line of an Ehrlich ascites tumor obtained by
sub-lethal in vitro irradiation between passages, for twenty-three
passages, as well as a series of single-cell clones form this sub-line.
In comparison to the parental cell line, all of the thus derived cell
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populations. with one exception. exhibited both enhanced anoxic radio­
resistance and increased NPSB content. In the presence of oxygen. all
sub-lines tested were as susceptible to the effects of radiation as the
parental line.
The role of GSB in cellular response to irradiation has been
further evaluated by experiments with fibroblast cell cultures from a
child suffering from 5-0%oprolinuria due to homozygous glutathione
synthetase deficiency. and from his healthy brother (Deschavanne et ale
1981a. 1981b; Midander et ale 1982). The deficient cells (containing
approximately 6� of control GSB) and normal cells were of equivalent
sensitivity when irradiated in an atmosphere of 100% oxygen. Bowever.
with radiation exposure under anoxic conditions. damage to the normal
cells was diminished. while the susceptibility of GSB-deficient cells
was unchanged. Radiosensitization of hypoxic cells by removal of GSB
has been demonstrated with diamide (Harris and Power 1973; Barris
1979). although doses in excess of that necessary to oxidize GSB to
GSSG are required. and with diethyl maleate (Bump et al. 1982). which
resulted in a greater than 95% depletion of GSB. Dethmers and Meister
(1981) have examined the euoxic radiosensitivity of a human cell line
after a 24 hour incubation with buthionine sulfoximine. an inhibitor of
GSB biosynthesis. which results is approximately a 95% depletion of 6SB
content. Compared to control cells. these GSB-deficient cells were
somewhat more radiosensitive. though radiation survival curves were not
generated (the highest dose resulted in a survival fraction of 0.5).
Theoretically. the importance of GSB as a determinant of hypoxic
cell radiosensitivity could result from a role in the detoxification of
11
radiation-induced toxins� such as free radicals� and/or the repair of
critically damaged cell structures. GSH can engage in one-electron
reactions with potentially harmful free radicals by hydrogen atom
donation� thus forming the relatively stable thiyl radical� and
ultimately GSSG. (reviewed by Kosower and Kosower 1976). Analysis of
the rate at which irradiation-induced single-strand DNA breaks were
repaired by the GSH-deficient human fibroblasts described earlier
failed to demonstrate a role for GSH under conditions of anoxia. In
contrast, GSH content was a determinant of the repair capacity of cells
following aerobic irradiation (Edgren et al. 1981). Thus, the precise
mechanism{s) by which GSH is involved in hypoxic cell defense against
radiation damage have not been determined. It is clear, however, that
the presence of oxygen serves to change the kinetics, magnitude� and/or
nature of the injury such that GSH is no longer protective.
Hypoxic, poorly vascularized cells within solid tumors, including
microscopic metastatic foci� limit the efficacy of both radiotherapy
and blood-borne chemotherapy (Kennedy et al. 1980a). One approach to
the problem of hypoxic cell radioresistance has been the development of
chemical radiosensitizers, which by virtue of their affinity for
electrons serve to mimic the effects of oxygen. A number of the more
effective radiosensitizers are metabolized by an oxygen-inhibited
pathway, resulting in the generation of cytotoxic species (Taylor and
Rauth 1980). Furthermore, incubation of cells under hypoxic conditions
with a variety of nitroimidazole sensitizers, such as misonidazole,
resulted in significant loss of GSH (Varnes et al. 1980; Astor et al.
1982; Biaglow et al. 1982; Hall et al. 1982). The potential signifi-
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cance of this depletion of GSH to either the mechanism(s) of radio­
sensitivity or the differential toxicity of these compounds towards
hypoxic cells has yet to be carefully analyzed.
2. Mechlorethamine and related nitrogen mustards. The ability of
alkylating agents such as the nitrogen mustards to react with a variety
of cellular nucleophiles, including sulfhydryl groups, has long been
recognized. The toxicity of mechlorethamine in experimental animals was
shown to be diminished by appropriately timed administration of
cysteine (Brandt and Griffin 1951) or cysteinamine (Peczenik 1953). In
this regard, it should be noted that in vitro exposure of cells to
cysteamine can result in a significant increase in intracellular GSH,
presumably by release from mixed disulfides with proteins (Revesz and
Modig 1965).
Analyses of the sulfhydryl content of murine tumors of varying
sensitivity to mechlorethamine and its N-oxide derivative have revealed
potentially significant correlations. Hirono (1961) generated resistant
variants of three ascites tumors by repeated passage through treated
animals and found in all three cases that their NPSH content was
increased. Among the original cell lines, relative drug susceptibility
did not correlate with the content of NPSH, suggesting a mechanistic
distinction between innate versus acquired resistance to this agent.
Similarly, Goldenberg (1969) demonstrated increased NPSH content in two
variants of a lymphoblast cell line made resistant to mechlorethamine
by in vitro exposure.
Comparing six murine tumors of varying sensitivity to merophan,
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an isomer of melphalan, Calcutt and Connors (1963) demonstrated a
relationship between inhibition of tumor growth by this agent and the
ratio of protein sulfhydryl to NPSH. Ball et al. (1966) evaluated the
content of protein, DNA, RNA, nucleotides, and NPSH in a melphalan­
resistant Yoshida sarcoma relative to the sensitive parental cell line
growing in the contralateral limb, and found the only difference to be
an increased level of NPSH in the resistant tumors. More recently,
Suzukake et al. (1982) have shown that an L1210 leukemia cell line made
resistant to melphalan and containing a 2-fold greater content of 6SB
could be re-sensitized by lowering its 6SB content. This was achieved
by incubation of the cells in medium deficient in cystine for 24 hours
prior to exposure to melphalan. A 2-fold increase in NPSH content has
also been documented for a melphalan-resistant subline of Chinese
hamster ovary cells (Begleiter et al. 1983).
3. Cyclophosphamide. Cyclophosphamide is a widely used nitrogen
mustard, which undergoes metabolic activation by hepatic mixed-function
oxidases. The generally accepted mechanism for the generation of active
metabolites involves oxidation to 4-hydroxycyclophosphamide, which
would be in tautomeric equilibrium with aldophosphamide. Nonenzymatic
cleavage of aldophosphamide results in the formation of two toxic
species, phosphoramide mustard and acrolein. Phosphoramide mustard is
considered to be the therapeutically active species while acrolein is
believed to be responsible for some aspects of host toxicity, such as
hemorrhagic cystitis. An alternative metabolic pathway for 4-hydroxy­
cyclophosphamide, involving loss of water to form a sulfhydryl-
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reactive species, has been suggested by the work of Draeger et al.
(1976) and Cates and Li (1982). Such sulfhydryl derivatives of cyclo­
phosphamide. themselves inactive, may serve as chemically stable
prodrugs. able to release by hydrolysis an active cyclophosphamide
metabolite (Peter and Hohorst 1979).
Working with mice. Gurtoo et al. (1981) have demonstrated
significant dose-dependent depletion of hepatic NPSH by both cyclo­
phosphamide and acrolein, but not phosphoramide mustard. They further
showed that cyclophosphamide-induced inhibition in weight gain in rats
was enhanced by coadministration of a GSH depletor, diethyl maleate.
and diminished by prior injections of cysteine. Cysteine also signifi­
cantly delayed the onset of hematuric cystitis in cyclophosphamide­
treated rats. Ashby e't al. (1976) have reported that injection of
cysteine or GSH prior to cyclophosphamide protected against terato­
genesis in pregnant rats. The antitumor activity of cyclophosphamide
appears not to be inhibited by cysteine administration (Gurtoo et al.
1981). In a similar manner. N-acetylcystine protected mice from the
toxic effect of isophosphamide. an analog of cyclophosphamide, without
interfering with its antitumor activity against L1210, allowing for the
safe administration of higher doses of isophosphamide, and thus
enhanced therapeutic efficacy (Venditti and Goldin 1974).
4. Nitrosoureas. Inhibition of GR in the erythrocytes of patients
receiving therapeutic doses of 1,3-bis(2-chloroethyl)-1-nitrosourea
(BCNU) was reported by Frischer and Ahmad (1977). Babson and Reed
(1978) have demonstrated that the isocyanates derived from the break-
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down of BCNU and other nitrosoureas are responsible for the irrevers­
ible inactivation of GR. They further suggest a correlation between the
inhibition of GR and nitrosourea-induced myelosuppression. There is.
however. disagreement about the ability of nitrosoureas other than BCNU
to inactivate GR (Frischer and Ahmad 1977; Shinohara and Tanaka 1979).
The relevance of this finding to the therapeutic action or toxicity of
BCNU is not at all clear. Administration of BCNU to tumor-bearing mice
resulted in a significant decrease in hepatic GSH content. accounting
for greater than SO� of the dose of BCNU. assuming a one-to-one
reaction stoichiometry (McConnell et al. 1979). It has been suggested
by Nathan et al. (1981) that inhibition of GR activity of alveolar
macrophages and other pulmonary cells may playa role in the develop­
ment of pulmonary toxicity observed following repeated therapy with
BCNU.
S. 6-Thiopurine. The cytochrome P-4S0 system activates 6-thio­
purine. in vivo or in vitro. to a reactive intermediate which binds
irreversibly through disulfide linkage to protein (Hyslop and Jardine
1981a. 1981b). In the presence of GSH. protein binding was diminished
and GSSG was formed. These authors therefore proposed that GSH competes
with protein sulfhydryls for reaction with the drug metabolite, purine-
6-sulfenic acid. forming thiopurine-GSH mixed disulfide. This then
reacts with another GSH molecule to regenerate 6-thiopurine and GSSG.
Depletion of hepatic GSH concentration by feeding rats a protein-free
diet prior to injection of radiolabeled 6-thiopurine resulted in
increased protein binding (Hyslop and Jardine (1981b). It is not yet
16
clear whether these findings are relevant to the toxicity of
6-thiopurine.
6. 4'-(9-acridiny1amino)methanesu1fon-m-anisidide (AMSA).
AMSA (NSC 141549) is one of the new antineoplastic agents arising from
investigations into the synthesis and antitumor activity of acridine
derivatives. Studying the pharmacokinetics of AMSA in mice, Cysyk et a1
(1977) reported a 40� drop in hepatic 6SB content within 2-3 hours
after intraperitoneal injection (100 mg/kg). They further proposed that
excretion in the bile of a 6SB-acridine thioether conjugate was the
predominant pathway of host metabolism and detoxification. A few years
later, Shoemaker et a1. (1980) demonstrated that biliary excretion of
AMSA, administered intravenously to rats (10 mg/kg), was markedly
diminished by pretreatment with diethy1 maleate, which itself resulted
in a 90% depletion of hepatic 6SB. A role for the mixed-function
oxidase system was also suggested by the observation that excretion was
enhanced by pretreatment with phenobarbital and diminished by pre­
treatment with metyrapone, agents with induce and inhibit, respec­
tively, the oxidase system (Shoemaker et a1. 1980). Careful analysis of
the fate of radio1abe1ed AMSA in rats has confirmed the principal
biliary metabolite to be a GSB thioether, with 6SB linked to the 5'
position of the anisidine ring. Conjugation with 6SB presumably occurs
after oxidation of AMSA by the mixed-function oxidase system to a
quinone-like diimine (Shoemaker et a1. 1982).
Although the importance of similar metabolic transformations of
AMSA within tumors is not known, it is clear that host tissue GSB- and
17
mixed function oxidase-dependent pathways are important determinants of
drug plasma levels (Shoemaker et al. 1980).
7. Generators of oxidant iniury.
a. Cells of the host immune system. Various cells of the host
immune system have the capacity to lyse tumor cells. An understanding
of the biochemical mechanisms underlying cell-mediated cytotoxicity
could be of considerable value for the development of effective
immunotherapy. Over the past eight years, numerous reports have
described oxygen-dependent mechanisms of cytolysis by granulocytes and
activated macrophages (Clark and Klebanoff 1975, 1977, 1979; Hafeman
and Lucas 1979; Simchowitz and Spilberg 1979; Borregaard and Kragballe
1980; Weiss 1980; Slivka et al. 1980; Weiss and LoBuglio 1980; Nathan
et al. 1979b; Nathan and Cohn 1980; Nathan and Klebanoff 1982; Clark
and Szot 1981). These effector cells can be stimulated to release H202
and other ROI at substantial rates, resulting in concentrations
sufficient to lyse target cells (Repine et al. 1974; Nathan and Root
1977; Nathan et al. 1979a). Indeed, exposure to H202 appears to be the
principal injurious event resulting in tumor cell lysis by phorbol
myristate acetate (PMA)-triggered granulocytes and macrophages, by
macrophages in the presence of antitumor antibody, and by activated
macrophages without the addition of triggering agents if the tumor
cells are first exposed to the cytophilic peroxidase of eosinophils
(EPO) (Nathan 1982). Nathan and co-workers have recently demonstrated
that the susceptibility of various tumor cells to effector cell-
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mediated lysis in these settings is largely a measure of the anti­
oxidant capabilities of the target cell. chiefly the GSH redox cycle
(Nathan et al. 1981; Arrick et al. 1982). This work will be discussed
in detail in Section I of Results. In short. we have found that the
relative susceptibility of six murine tumors to lysis by H202 correl­
ated with cellular GSH content. Further. depletion of GSH. or inter­
ference with its utilization in the GSH redox cycle by inhibition of
GPO or GR. sensitized tumor cells to various forms of peroxide­
dependent lysis.
It should be noted that self protection of granulocytes and
macrophages from the H202 and ROI they themselves generate is probably
a function of GSH-dependent detoxification as well. Basford (1980) has
recently reviewed the numerous reports of auto-oxidative damage in
leukocytes with enzyme defects affecting the GSH redox cycle. such as
inherited deficiencies in GR or GSH synthetase.
b. Quinone-containing drugs. Antineoplastic agents which contain
a quinone moiety are believed to undergo metabolic activation by
microsomal enzymes to free radicals. themselves toxic. which can
interact with oxygen to generate ROI via superoxide anion (Bachur et
al. 1978). Examples of such drugs include doxorubicin and daunorubicin
(benzanthraquinones). mitomycin C and streptonigrin (N-heterocyclic
quinones). and lapachol (a naphthoquinone). While it is believed that
such oxygen-dependent metabolism of streptonigrin forms the basis of
its antitumor activity. the observation by Teicher et al. (1981) that
mitomycin C and doxorubicin are preferentially toxic to hypoxic tumor
19
cells suggests the existence of oxygen-independent or -inhibitable
pathways of metabolic activation. Still, the generation of free
radicals and ROI by these agents may be an important determinant of
drug toxicity.
In particular, substantial evidence now exists implicating a major
role for host GSB metabolism as a determinant of host tissue damage by
doxorubicin, principally cardiac toxicity. Analysis of the antioxidant
defenses of mouse heart has identified selenium-dependent GPO, and thus
the GSB redox cycle, as a major pathway for the detoxification of ROI,
such as that generated by doxorubicin (Doroshow et al. 1980). It has
further been demonstrated that administration of doxorubicin to mice
resulted in a dose-dependent decrease in the activity of cardiac GPO
with no effect on the hepatic enzyme (Doroshow et al. 1980). Obtaining
similar results with doxorubicin-treated rabbits, Revis and Marusic
(1978) also noted a significant decrease in the cardiac content of
selenium after drug treatment. GSB content was diminished slightly in
both liver and heart after injection of mice with doxorubicin (Doroshow
et al. 1979; Olson et al. 1980). The lethal toxicity of doxorubicin to
mice could be markedly increased by prior depletion of GSB by pre­
treatment with diethyl maleate, itself without lethality (Olson et al.
1980). Working with isolated hepatocytes, Babson et ale (1981) have
shown that pretreatment with BCNU, resulting in a )90% inhibition of GR
and a 70% depletion of GSB, augmented the toxicity of doxorubicin and
increased the degree of lipid peroxidation. Equivalent GSB depletion by
diethyl maleate had no effect, indicating a predominant role for GR as
the rate-limiting component of the GSB redox cycle in this system.
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Administration of various antioxidants to mice, such as tocopherol,
cysteamine, and N-acetylcysteine, has been shown to diminish the host
toxicity of doxorubicin, without interference with its antitumor
activity. resulting in an increase in the therapeutic index (Myers et
al. 1977; Freeman et al. 1980; Doroshow et al. 1981).
In summary, as regards generators of oxidant injury, be they cells
of the host immune system or quinone-containing drugs, GSH metabolism
of both tumor and host may be an important detoxification pathway,
influencing both toxicity and antineoplastic efficacy.
8. Sulfhydryl-reactive antineoplastic agents. A high degree of
sulfhydryl reactivity is a shared feature of a variety of experimental
antineoplastic agents, many of which have been isolated from natural
sources. The most recent overall review of the in vitro sulfhydryl
reactivity of such antitumor alkylating agents was provided by Fujita
and Nagao (1977). However, very little information concerning the
interaction of such compounds with intracellular sulfhydryl groups,
such as GSB, is available. As will be detailed in Section II of
Results, we have studied the effect of four sesquiterpene lactones, and
the related diterpene jatrophone, on tumor cell GSB content. We have
found these agents to be potent depletors of cellular GSB. Furthermore,
resynthesis of GSH after drug exposure was an important component of
tumor cell response and repair; inhibition of GSB resynthesis markedly
augmented cytolysis (Arrick et al. 1983). Jackson et al. (1976) have
reported that incubation of Yoshida sarcoma or L1210 cells with
cytembena (cis-p-4-methoxybenzoyl-p-bromoacrylate), an anticancer drug
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susceptible to nucleophilic addition by sulfhydryls, resulted in
substantial depletion of GSH. It is clear that as sulfhydryl-reactive
agents gain wider use in the treatment of cancer, an understanding of
the role of cellular GSH in detoxification and protection of vital cell
structures becomes all the more important.
B. Toxification.
1. Azathioprine. Azathioprine is a prodrug which is converted
into 6-thiopurine and various methylnitroimidazole metabolites.
Thiolysis by GSH, with the formation of the GSH-imidazole adduct, is
believed to be the major route of azathioprine toxification (de Miranda
et al. 1973). Kaplowitz and Kuhlenkamp (1978) have implicated a role
for GSH S-transferases in the thiolysis of azathioprine; both the
depletion of hepatic GSH and formation of 6-thiopurine observed after
azathioprine administration were inhibited by prior inhibition of GSH
S-transferases with probenicid.
Chalmers (1974) has shown that the GSH-imidazole adduct discussed
above is further metabolized to 5-thio-l-methyl-4-nitroimidazole. This
compound, itself without activity as an immunosuppressant or stimulant,
significantly diminished the degree of immunosuppression obtained with
a concurrent injection of 6-thiopurine (Garattini et al. 1974).
2. Bleomycin. Bleomycin, a mixture of two structurally similar
glycopeptides, is believed to act as an antitumor agent via an oxygen­
dependent mechanism of DNA cleavage. Specifically, a ferrous iron-
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bleomycin complex reacts with oxygen to generate superoxide anion. and
the iron-bleomycin complex itself is oxidized to the ferric state.
Caspary et al. (1981) have recently reported that GSB is able to bind
to this ferric iron-bleomycin complex and reduce it to the active
ferrous-iron complex. They therefore proposed a catalytic redox cycle
in which reducing equivalents from GSB are ultimately transferred to
oxygen resulting in the formation of superoxide anion and other ROI.
Other investigators have not detected significant interaction of GSB
with the ferric iron-bleomycin complex. while still reporting enhanced
DNA strand scission by ferrous iron-bleomycin in the presence of GSB
(Antholine et al. 1981). A role for GSB in the toxification of
copper(II)-bleomycin. a form of the drug with in vivo activity yet
without activity in cell-free systems. has been suggested by the work
of Freedman et al. (1982). They suggest that metal-free bleomycin first
chelates copper(II). forming an inactive complex which upon entry into
cells is converted back into metal-free bleomycin by the action of GSB.
via a copper(l) intermediate. This then binds any available iron(II).
thus forming the active species.
Involvement of GSB in intracellular reductive toxification. such
as in the iron-bleomycin catalytic cycle. may be characteristic of
other drug interactions. Neocarzinostatin is another antitumor agent
which results in oxygen-dependent cleavage of DNA in a manner which is
dependent upon the presence of thiols. though evidence has been
presented both for (Sim and Lown 1978) and against (Kappen and Goldberg
1978; Kappen et al. 1980) a role for copper(ll) in this process.
Recently. Myers et al. (1982) have reported that the oxidative
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destruction of erythrocyte ghost membranes by an iron-doxorubicin
complex is dependent upon the presence of GSH.
c. Delivery.
1. Methotrexate. The uptake of methotrexate by cultured rat
hepatocytes has been shown to be significantly accelerated by the
addition of GSH to the medium (Leszczynska and Pfaff 1982). A role for
externally disposed membrane sulfhydryl groups was indicated by the
demonstration that methotrexate uptake was inhibited by exposure of the
cells to an analog of diamide which is unable to enter cells. and thus
oxidizes only extracellular sulfhydryl groups (the bis-N'-methyl
quaternary salt of diazenedicarboxylic acid bis(N'-methylpiperazide».
GSH reversed this inhibition. presumably by regeneration of critical
sulfhydryl groups. Leszczynska (1981) has reported that both the
pharmacokinetics of clearance from blood as well as ultimate tissue
distribution of rifamycin SV in rats is significantly affected by
coadministration of GSH. but not GSSG. Interestingly, GSH served to
enhance drug uptake by the lung, while reducing drug levels in the
liver.
It should be kept in mind that host tissue GSH-dependent metab­
olism and excretion of systemically administered anticancer agents,
as discussed for AMSA and azathioprine, are obvious determinants of the
delivery of active drug to its target. A role for GSH metabolism as a
determinant of drug uptake by cells, such as suggested above for
methotrexate, represents a different type of GSH-drug interaction.
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2. y-Glutamyl derivatives as possible prodrugs. It has been
suggested by Meister and Griffith (1979) that y-glutamyl derivatives
of some chemotherapeutic agents might be transported into certain
tumors more readily than the agents themselves since many tumors
exhibit increased y-glutamyl transpeptidase activity. The feasibility
of this approach to prodrug targetting has been demonstrated for agents
directed to the kidney (Wilk et al. 1978; Orlowski et al. 1980).
D. Therapeutic interactions.
From the discussion above# it is evident that many antineoplastic
agents alter the GSB status of host and/or tumor by depletion of
cellular GSB content and/or inhibition of associated enzymes.
Conceivably# this could influence both the toxicity and therapeutic
efficacy of concurrent therapeutic interventions. In other words#
changes in GSB metabolism may constitute the biochemical basis of some
therapeutic interactions. Examples of a few such interactions# both
actual and theoretical# will illustrate this point.
Inhibition of GR by BCNU# as noted above# augmented macrophage­
mediated tumor cell lysis (Nathan et al. 1981). Similarly# the in vivo
antitumor activity of glucose oxidase-generated B202 was enhanced by
BCNU at sub-therapeutic yet GR-inhibiting doses (Nathan and Cohn 1981).
In view of the role of the GSB redox cycle in the antioxidant defenses
of the heart# BCNU might serve to increase the cardiotoxicity of
doxorubicin. Another possibility is that the effectiveness of bleomycin
may be dependent upon a properly functioning GSB redox cycle within the
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tumor target, and thus BCNU would interfere with the action of
bleomycin. Inhibition of GR could result in increased protein binding
of 6-thiopurine metabolites, leading to enhanced toxicity. Finally,
inactivation of the GSH redox cycle by BCNU could impair cellular
response to radiation damage.
It has previously been pointed out that alterations in GSH content
can affect the detoxification and effectiveness of a variety of anti­
neoplastics, including nitrogen mustards, cyclophosphamide, and AMSA.
Such alterations in GSH content can arise as a result of the concurrent
use of agents which deplete cellular GSH, such as misonidazole, BCNU,
and sesquiterpene lactones. GSH is translocated out of cells, and thus
intracellular GSH may be the major source of reducing equivalents for
the external surface of cell membranes (Griffith and Meister 1979a).
This raises the possibility that GSH depletion may result in diminished
permeability of cells to methotrexate. Griffith and Meister (1979b)
have reported that systemic administration to mice of an inhibitor of
y-glutamyl transpeptidase resulted in a three-fold increase in plasma
GSH. Thus, the pharmacokinetics and distribution of methotrexate may
also be altered by agents which inhibit human y-glutamyl trans­
peptidase, such as the antineoplastic glutamine antagonists 6-diazo-5-
oxo-L-norleucine (DON) (Tate and Ross 1977) and a-amino-3-chloro-2-
isoxazoline-5-acetic acid (AT-125) (Allen et al. 1980).
In summary, a role for GSH metabolism as a determinant of
therapeutic efficacy has been suggested for a wide variety of anti­
neoplastic interventions (Table I). In this thesis, I will discuss the
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importance of tumor cell GSB as a determinant of susceptibility to
lysis by two forms of injury: exposure to oxidant injury (Section I of
Results). and incubation with sulfhydryl-reactive antineoplastics
(Sections II and III of Results).
TABLE I
Examples of Antineoplastic Interventions for
which GSB Metabolism may Influence Therapeutic Efficacy
A. Detoxificat ion
1. Radiation
2. Mechlorethamine and related nitrogen mustards
3. Cyclophosphamide
4. Nitrosoureas
s. 6-Thiopurine
6. AMSA
7. Generators of oxidant injury
a. Cells of the host immune system
b. Quinone-containing drugs
8. Sulfhydryl-reactive agents
B. Toxification
1. Azathioprine
2. Bleomycin
C. Delivery
1. Methotrexate
2. y-Glutamyl derivatives as possible prodrugs
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MATERIALS AND METHODS
Eagle's minimum essential medium, alpha variant (a-MEM),
streptomycin, penicillin, and horse serum were obtained from Flow
Laboratories. The following were from Sigma: glucose oxidase (type V),
Triton X-I00, dimethyl sulfoxide, 5-sulfosalicylic, CONB, NADPH, GSB,
GSSG. yeast GR, catalase (thymol free), 3-amino-l.2,4-triazole,
5,5'-dithiobis-(2-nitrobenzoic acid), mitomycin C, Ara-C, and
vinblastine sulfate. Superoxol (30� hydrogen peroxide) was from
Mallinckrodt Chemical Works. PM! was obtained from Consolidated
Midland. Dulbecco's phosphate-buffered saline and Eagle's minimum
essential medium (MEM), provided as a kit in which the separate amino
acids can be added as desired, was obtained from Grand Island
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Biological Co. Na2 Cr04 was from New England Nuclear. DL-Buthionine-
SR-sulfoximine (BSO) was either synthesized and provided by Dr. Owen
Griffith of Cornell Medical College, Department of Biochemistry, or it
was purchased from Chemical Dynamics Corp. The following compounds were
obtained through the courtesy of Dr. V. L. Narayanan, Drug Synthesis
and Chemistry Branch, and Dr. 1. D. Douros, Natural Products Branch,
Division of Cancer Treatment, National Cancer Institute: helenalin (NSC
85236); vernolepin (NSC 106398); elephantopin (NSC 100046);
eriofertopin (NSC 283439); jatrophone (NSC 135037); maytansine (NSC
153858); BCNU (NSC 409962); and doxorubicin hydrochloride (NSC
123127).
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Tumors. Tumor cell lines were maintained by intraperitoneal
passage in histocompatible mice as described (Nathan et al. 1979a,
1981). For experiments, these tumors were grown in stationary
suspension cultures in a-MEM, supplemented with 100 pg/ml of
streptomycin, 100 U/ml of penicillin, and 10� heat-inactivated horse
serum. 1774 cells were maintained in spinner culture with 5� fetal
bovine serum plus antibiotics.
Effector Cells. Activated macrophages and granulocytes were
collected as described (Nathan et al. 1981). In brief, effector cells
were obtained by peritoneal lavage of CD2Fl female mice 10-42 days
after i.p. injection of viable BCG (BCG-activated macrophages) or 12-18
h after i.p. injection of thioglycollate medium (granulocytes).
Use of Pharmacologic Agents. GSH depletion by BSO (0.2 mM) was
achieved by incubation of cells in a-MEM, 10� horse serum at 370C in
5� CO2, 95� air. BSO stock solution (20-45 mM) was stored at OOC
for up to 3 weeks before use. CDNB was dissolved in absolute ethanol
just before use and added to tumor cells in a-MEM, 5� horse serum
(final ethanol concentration, 0.2-1�). In some experiments, CDNB was
included in the 4.5-h cytolysis assay. In other experiments, tumor
cells were pretreated with CDNB for 15 min at 370C in the presence of
BSO (0.2 mM), washed twice, and then assayed for GSH content and
susceptibility to lysis in the presence of BSO. The inclusion of BSO
was necessary to prevent resynthesis of GSH by the CDNB-treated cells.
In experiments with SLs and other potential sulfhydryl-reactive agents,
tumor cells in a-MEM, 5� horse serum (1.0 x 106 - 1.7 x 106/ml)
o
were incubated at 37 C with the test compounds dissolved in dimethyl
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sulfoxide, or vehicle alone, for the indicated times. Dimethyl
sulfoxide content ranged from 0.1 to 1� and did not affect GSB levels
Sl
or specific release of Cr from the cells. Inhibition of GR by BCNU
6
was as follows: In Section I of Results, tumor cells (S x 10 - 1 x
10'/ml in a-MEM, 1� horse serum) were incubated with BCNU or vehicle
(final ethanol concentration, 0.09�) at 3'oC for 10 min, and then
washed. In Section III of Results, tumor cells (l.S x 106 - 3 x
106/ml in cystine-free MEM, S� horse serum) were incubated with BCNU
or vehicle alone (final dimethyl sulfoxide concentration, O.S�) at
3'oC for IS min, and then washed. BCNU was stored at -20oC and
dissolved immediately before use.
Biochemical Assays. To measure total cellular glutathione (GSB
plus GSSG), 1 x 106 - 2 x 106 tumor cells were washed 3 times in
ice-cold phosphate buffered saline, lysed with 0.2� Triton X-I00, and
made to contain 2.S� sulfosalicylic acid in a total final volume of
0.12 mI. After centrifugation, acid-soluble extracts were stored at
-'OoC and assayed within 2 weeks by a minor modification of the
method of Tietze (1969), in which the rate of S,S'dithiobis-(2-nitro-
benzoic acid) reduction obtained with O.OS ml of extract was analyzed.
With each assay a standard curve was generated with known amounts of
GSB (0-2 nmol/O.OS ml) in the same concentrations of Triton X-lOO and
sulfosalicylic acid as the samples. Total glutathione is expressed as
nanomoles of the tripeptide per milligram of cell protein. Extracts of
cells treated with compounds that were found to cause GSB depletion
were mixed with known amounts of GSB and then assayed to rule out the
presence of an inhibitor of the Teitze assay, which might have
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accounted for the observed loss of GSB. The activity of glucose oxidase
used in cytolysis experiments was measured with the scopoletin assay
for B202 as described (Nathan and Root 1977). GR was assayed by the
method of Roos et a1. (1979) as described by Nathan et al. (1981). GPO
activity was measured by the method of Paglia and Valentine (1967).
Catalase was measured according to the method of Baudhuin et al.
(1964). Superoxide dismutase was assayed according to the method of
McCord and Fridovich (1969). GSB S-transferase activity was measured
with CDNB (1 mM) as substrate by the method of Habig et al. (1974).
Protein content was determined by the method of Lowry et al. (1951)
using bovine serum albumin as standard.
Cytolysis Assays. Tumor cells were labeled with Na251cro4 as
described (Nathan et al. 1979a, 1981). Calculation of percent specific
release was as suggested by Nathan et al. (1979a). In some experiments,
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the Cr release assay was validated by comparison to the trypan blue
dye exclusion test as described (Nathan et al. 1981).
In Section I of Results, cytolysis assays were performed as
follows: susceptibility of tumor cells to cytolysis by H202 was
determined by incubation of 4 x 104 labeled cells with dilutions of
glucose oxidase or preformed B202 (Superoxol, 8.82 M), plus BSO (0.2
mM) in 0.22 ml of a-MEM, 5� horse serum at 370C for 4.5 h. The amount
of glucose oxidase or preformed B202 causing 50� specific release of
the 51Cr label (LD50) was determined by interpolation. For evaluation
of tumor cell susceptibility to cell-mediated cytotoxicity, 2 x 104
labeled tumor cells were incubated with various numbers of effector
cells in 0.2 ml of a-�UEM, 5� horse serum in the presence of 100 nglml
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PM! or vehicle alone (0.033% dimethyl sulfoxide) plus BSO (0.2 mM) for
o
5 h at 37 C. Each reported data point represents the mean of
triplicate determinations. Effector:target ratios are based on the
proportion of effector cells in the peritoneal cell population used in
each experiment, as determined by differential counting. The presence
of BSO during the cytolysis assay did not effect the lysis of cells
which had not previously been treated with CDNB.
In Section II of Results, cytolysis was studied in 2 experimental
settings: (a) 4 % 104 labeled cells were incubated with various
concentrations of lytic agent or vehicle alone (0.1-1% dimethyl
sulfoxide) in the presence or absence of BSO (0.2 mM) in 0.22 ml of
a-MEM, 5' horse serum at 370C for 18 h. (b) Cells (1.5 x 106/ml in
a-MEM, 5� horse serum) were incubated with various concentrations of
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vernolepin or vehicle alone (0.1� dimethyl sulfoxide) plus Na2 Cr04
for 1 h, washed extensively (4 centrifugations), and then incubated in
a-MEM, 5� horse serum (1.5 x 105 in 1 ml) for 18 h. BSO (0.2 mM) was
added to the medium at various times as indicated in each experiment.
After the 18 h incubation, supernatant (0.1 ml for a, 0.5 ml for b) was
removed after centrifugation for gamma counting and the percent
specific release was calculated. The LDSO was determined from a
dose-response curve by interpolation. In protocol b, if 51Cr was
measured after 26 h rather that 18 h, the LDSO was reduced by a
factor of 1.2 while the spontaneous release increased by a factor of
1.4. Each reported data point represents the mean of triplicate
determinations.
In Section III of Results, cytolysis was studied in 2 experimental
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settings: (a) P815 cells were washed into cystine-free MEM. 5� horse
serum and incubated for 1 h with vernolepin. or vehicle alone (0.1-0.5�
51 6
dimethyl sulfoxide) with Na2 Cr04 (1.5 x 10 Iml). washed. and then
incubated for 18-20 h in MEM. 5� horse serum (1.5 x 105/ml in 0.5 ml)
with or without cystine (0.09 mM). with or without BSO (0.2 mM). At
this time. cells were centrifuged and 0.2 ml of supernatant sampled for
gamma counting. Reported data points represent the mean of duplicate
or triplicate determinations. as indicated. (b) 4 x 104 labeled cells
were incubated with dilutions of glucose oxidase plus vernolepin or
vehicle alone (0.1� dimethyl sulfoxide) in the presence or absence of
o
BSO (0.2 mM) in 0.22 ml of u-MEM. 5� horse serum at 37 C for 5 h. At
this time. 0.1 ml of supernatant was removed for gamma counting. Each
reported data point represents the mean of triplicate determinations.
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RESULTS
I. Oxidative Cytolysis
A. Introduction
As discussed in the Introduction, the secretion of H202 by
granulocytes and activated macrophages following appropriate stimula­
tion constitutes the main cytolytic component of effector cell response
in some in vitro systems. Comparison of the susceptibility of various
tumor cell lines to lysis by H202 or peroxide-producing leukocytes
reveals considerable variation (Nathan 1979; Nathan et al. 1979a,
1981). Thus, a potentially cytolytic event is perhaps best viewed as an
interaction in which peroxide generation by leukocytes and the anti­
oxidant capacity of the target cell each playa significant role. The
principal pathways of H202 detoxification in cells are the GSH
oxidation-reduction cycle and catalase.
In this section, I will present data indicating a correlation
between the susceptibility of six murine tumor cell lines to H202-
mediated lysis and their content of GSH. I will further document
sensitization of tumor cells to lysis by a flux of H202, such as that
generated by the enzyme glucose oxidase or peroxide-producing
leukocytes, as a result of GSH depletion or inhibition of GR, but not
inhibition of catalase.
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B. Results
Correlation of GSH Content with Susceptibility to Oxidative
Cytolysis. Four lymphomas, a mastocytoma, and a histiocytoma, spanning
a 54-fold range in susceptibility to lysis by H202, were studied. We
evaluated the susceptibility of 51Cr-Iabeled tumor cells to lysis by a
flux of H202 by measu�ing the 51Cr released into the supernatant after
a 4.5-h incubation with varying amounts of the H202-generating enzyme,
glucose oxidase. The levels of catalase, GR, or GPO in these cells did
not correlate with the resistance of the tumors to H202 (Nathan et al.
1981). In contrast, the cellular content of glutathione (per mg of cell
protein) correlated with the logarithm of the flux of peroxide causing
50% lysis (Fig. 3).
Depletion of Tumor Cell GSH by Buthionine Sulfoximine (BSO). BSO
is a selective inhibitor of y-glutamylcysteine synthetase (Griffith and
Meister 1979c). GSH depletion in the presence of BSO reflects ongoing
GSH catabolism, efflux, and cell division in the absence of new
synthesis. Incubation of intact P815 mastocytoma or P388 lymphoma cells
with 0.2 mM BSO resulted in a gradual decline in cellular GSH (Fig. 4).
Tumor cell GSH levels were reduced to 50% of normal values after 4.5-5
h of exposure to BSO. Incubation with BSO for 15 h or longer resulted
in )90% depletion of GSH. Similar kinetics of GSH depletion were
observed with the TLX9 lymphoma (not shown). Incubation of P815 cells
with 0.02 mM BSO resulted in a slower rate of GSH depletion, while 1 mM
was no more effective that 0.2 mM BSO (not shown). Thus, 0.2 mM BSO,
which produced complete inhibition of the isolated enzyme (Griffith and
Meister 1979c), is assumed to achieve virtually complete inhibition of
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Figure 3. Correlation of the GSB content of 6 tumor cell lines
with their sensitivity to enzymatically generated B202• The
latter is expressed as the logarithm of the activity (nanomoles
of B202'min) of glucose oxidase necessary to cause SO� lysis of
the tumors in a 4.S-h S1Cr-release assay. Each point represents
1 tumor and is the mean of 3-6 GSB determinations and 2-19 LDSO
determinations.
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Figure 4. Time course of GSB depletion by BSO. The intact
cells were incubated with 0.2 mM BSO in a-MEM, 10% horse
serum at 370C for the indicated times and then assayed for
glutathione content. Data for P81S are from 7 experiments
with initial GSB levels of 26.1 ± 2.1 nmol/mg of protein.
Data for P388 are from 1 experiment in which the initial GSB
level was 11.6 nmol/mg of protein.
38
GSB biosynthesis in intact cells grown in tissue culture medium. In all
sub�equent experiments# BSO was used at a concentration of 0.2 mM.
Incubation of P815 cells with 2 mM BSO for 18 h# or 0.2 mM for up
to 3 weeks# was nontoxic# as judged by exclusion of trypan blue.
Furthermore# the rate of cell division of P815 cells was unaffected by
BSO (generation time of -11 h). Incubation of P388 cells with BSO for
16 h had no significant effect on the specific activities of GR# GPO#
catalase# or superoxide dismutase (not shown). Inclusion of BSO in the
assay reaction mixture was similarly without effect for any of the
above enzymes (not shown).
Depletion of Tumor Cell GSB by CDNB. GSB S-transferases catalyze
the formation of thioether conjugates between GSB and a wide variety of
electrophilic compounds (Habig et al. 1974). CDNB serves as an
effective substrate and has previously been used to reduce the GSB
content of intact cells (Novogrodsky et al. 1979). We first verified
the presence of GSB S-transferase in P815 lysates (0.05 unit/mg of
protein). We then measured the GSB content of P815 and P388 cells after
exposure to CDNB for 15 min (Fig. 5). Treatment of P815 cells with CDNB
resulted in a dose-dependent loss of GSB# with a maximal depletion of
approximately 70� of initial values obtained with 10 �M CDNB. At
concentrations above 30 �M, CDNB was toxic to both P815 and P388#
51
as judged by significant elevation in the spontaneous release of Cr
over 4.5 h.
The activities of GR# GPO# catalase, and superoxide dismutase in
lysates prepared from P388 cells treated with 20 �M CDNB for 15 min and
then washed twice were not significantly different from untreated
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control lysates (not shown). Howeverl experiments with yeast GR
demonstrated concentration-dependent inhibition by CDNB1 with maximal
inhibition of 42� achieved with 35 �M CDNB. Inhibition of GR by CDNB
was not dependent upon pre-exposure of the enzyme to CDNB1 in either
the presence or absence of NADPH1 and enzyme activity could be restored
by dilutionl suggesting a reversiblel noncovalent mode of inhibition.
Effect of GSH Depletion on Susceptibility of Tumor Cells to Lysis
�2Q2. Tumor cells were exposed to a continuous flux of nascent
H202 by the addition of glucose oxidase to the glucose-containing
mediuml or where indicatedl were exposed to a bolus of preformed H202•
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As before, the susceptibility of Cr-labeled tumor cells to lysis by a
flux of H202 was determined after a 4.S-h incubation with varying
amounts of glucose oxidase. In one such experimentl incubation of P81S
cells with BSO for 19 h reduced the amount of glucose oxidase required
51
to cause 50% specific Cr release (LDSO) by a factor of 3.5 (Fig. 6).
The correlation between the time of incubation with BSO, and therefore
the extent of GSH depletionl and increased sensitivity to lysis by
glucose oxidase-generated H202 is illustrated in Figure 7 for P81S.
With P388, a cell line with a native sensitivity to H202 about 4-fold
greater than that of P81S, incubation with BSO for 13-16.5 h reduced
the LDSO for glucose oxidase by a factor of 1.68 ± 0.1 (5 experiments).
In contrastl incubation of TLX9 cells with BSO for 24 h reduced the GSH
content to <S� of its initial level (18.1 nmol/mg of protein)1 yet did
not affect sensitivity to lysis by glucose oxidase. In all casesl lysis
by glucose oxidase was abolished by exogenous catalase (not shown).
The inclusion of CDNB with the labeled tumor cells and glucose
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Figure 6. Effect of GSB depletion on the sensitivity of P81S
cells to lysis by a flux of H202• 51Cr release was measured
after a 4.S-h incubation with dilutions of glucose oxidase.
Prior to assay. the tumor cells were incubated with (0) or
without (.) 0.2 mM BSO for 19 h. Points are means of triplicate
SI
determinations. S.E. averaged 1.1�. Spontaneous release of Cr
label was <8�.
•4
(/)
• •
(/)
�
0
-
�
-
3·s
-
"if)
c
Q)
f,/)
c
Q)
2(/)
0
Q)
....
u
.£
Q)
::>
-
0
Q)
a::
o 4 8 12
Hours with SSO
16 20
Figure 7. Time course of the effect of O.Z mM BSO on sensitivity of
P81S cells to lysis by a flux of H202• Relative increase in sensi­
tivity to lysis = LDSO(control)/LDSO(treated) for the activity of
glucose oxidase causing SO� lysis in 4.S h. LDSO values were calcu­
lated by interpolation from curves like those in Figure 6. LDSO
(control) averaged 1.04 ± 0.04 nmol of HZOZlmin (N=8). Spontaneous
release averaged 8.1 ± 1.6% (N=IS). The fit of the data to an
exponential curve is shown (r2=0.7Z).
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oxidase during the 4.S-h cytolysis assay resulted in a dose-dependent
increase in lysis of P81S. reaching a 4- to 6-fold relative increase in
sensitivity to lysis with IS �M CDNB (Fig. 8). When the same experiment
was performed with P81S cells which had already been depleted of GSB by
prior incubation with BSO for 13 h. CDNB did not result in increased
lysis relative to BSO-treated cells in the absence of CDNB (Fig. 8).
Exposure of labeled P81S cells to 10-30 �M CDNB for IS min prior
to but not during the 4.S-h incubation with glucose oxidase made the
cells more susceptible to lysis by a factor of 1.70 ± 0.11 compared to
vehicle-treated controls (10 experiments). BSO was present during the
4.S-h cytolysis assay to prevent resynthesis of GSB by the treated
cells (see below).
It has previously been shown that inhibition of catalase by
incubation of P81S cells with 2S mM aminotriazole is not associated
with increased lysis by either enzymatically generated B202 or pre­
formed B202 added as a bolus (Nathan et al. 1981; see Fig. 14 below).
The data presented in Table II confirm these observations and further
demonstrate that whereas depletion of GSB is similarly without effect
on tumor cell lysis by preformed B202• the combination of GSB depletion
and catalase inhibition markedly sensitizes P81S cells to a bolus of
B202• Such synergy is not evident when glucose oxidase is used to
deliver a steady flux of B202•
The marked sensitization to B202-mediated lysis observed with GSB
depletion by BSO and CDNB was also evident when cytotoxicity was
evaluated by trypan blue exclusion (not shown). confirming the validity
SI
of the Cr release assay under the experimental conditions. Under
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Figure 8. Effect of CDNB on sensitivity of PS1S to lysis by a
flux of H202• CDNB at the indicated concentrations was
included in the 4.S-h incubation with glucose oxidase and the
increase in sensitivity to lysis relative to no CDNB (LDSO
(-CDNB)/LDSO(+CDNB» was determined as in Figure 7 for normal
cells (.) and cells which had been incubated with 0.2 mM BSO
for 13 h to deplete their GSB (A). For the normal cells,
LDSO(-CDNB) = 1.25 ± 0.04 nmol of H202/min (N=3). For the BSO­
treated cells, LD50(-CDNB) = 0.34 nmol of H202/min.
Spontaneous release averaged 12.6 ± 1.S% (N=14).
Table II
Effect of GSH Depletion and/or Inhibition of Catalase
on the Sensitivity of P815 Cells to Lysis by
Glucose Oxidase or Preformed H202
R
Treatment
Relative increase in
*
sensitivity to lysis by
Glucose oxidase
+ glucose
Experiment 1
BSO 3.5 1.2
Aminotriazole 1.2 1.0
BSO + aminotriazole 3.3 2.6
Experiment 2
BSO 1.9 1.0
Aminotriazole 0.9 1.2
BSO + aminotriazole 2.3 3.9
*
LD50(control)/LD50(treated) for the activity of glucose
oxidase or concentration of H202 added as a bolus causing
50% specific 51Cr release in 4.5 h in u-MEM, 5% horse serum.
LD50(control) for glucose oxidase = 1.01 nmol of H202/min
in both experiments. LD50(control) for preformed H202 =
5.60 x 10-4 M in experiment 1 and 7.28 x 10-4 M in
experiment 2. Average spontaneous 51Cr release = 5.9 ± 0.3%
(N=16).
DTumor cells were incubated in u-MEM, 10% horse serum with
0.2 mM BSO for 19 h (experiment 1) or 18 h (experiment 2).
Treatment with aminotriazole (25 mM) was for 45 min prior
to and during the cytolysis assay.
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these same conditions, neither BSO, CDNB, aminotriazole, nor any
combination of these agents elevated the spontaneous release of SlCr
from the tumor cells.
Recovery from the Effects of BSO and CDNB. P81S cells were
incubated with BSO for 20 h and then incubated without BSO for 0, 5,
10, or 20 h, at which time the cells were assayed for both GSH content
and sensitivity to lysis by glucose oxidase (Table III). By 5 h,
restoration of cellular GSH was modest, perhaps due to slow dissoci­
ation of the enzyme-inhibitor complex, and the cells continued to
exhibit increased sensitivity to lysis, although some recovery was
evident. Resynthesis of GSH to 89% of initial levels, seen at 10 h, was
associated with near-complete recovery of the innate resistance to H202
of untreated cells.
In a similar fashion, P81S cells were treated with 25 �M CDNB for
15 min, and then incubated with or without BSO. At various times the
cells were assayed for cellular GSH (Fig. 9A), or for sensitivity to
lysis by glucose oxidase relative to untreated controls (Fig. 9B).
Recovery of both parameters after exposure to CDNB was rapid and was
inhibited completely by BSO. The slightly increased resistance to
H202-mediated lysis displayed by cells which had been treated with CDNB
and then incubated without BSO for 4.5 h may have reflected supernormal
levels of GSH, although such a correlation is not firm (Fig. 9 and
Table III).
It was expected that incubation of cells with y-glutamylcysteine
might obviate the need for a functional Y-glutamylcysteine synthetase
and thereby specifically bypass the effect of BSO. However, attempts to
47
Table III
Time Course of Recovery of Cellular GSB and Resistance to H202
After Incubation of P815 Cells with BSO for 20 h
% of Relative increase
Treatment ini tial
GSH=
in sensi tivi�y
to lysis
None 100 1.0
20 h wi th BSO@ 7 3.1
20 h with BSO, then 5 h without 11 2.1
20 h with BSO, then 10 h without 89 1.1
20 h with BSO, then 20 h without 140 1.0
-Initial GSH = 33.8 nmol/mg of protein.
*
LD50(control)/LD50(treated) for the activity of glucose oxidase
causing 50% lysis in 4.5 h in a-�ffiM, 5% horse serum. LD50(control)
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= 1.3 nmol of H202/min. Spontaneous release of Cr averaged
5.7 ± 0.3� (N=5).
@Incubations in a-MEM, 10% horse serum at 37oC. BSO, 0.2 mM.
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Figure 9. Time course of recovery of cellular GSH and resistance to B202
after treatment of P81S cells with CDNB. Cells were treated with CDNB (o.A)
or vehicle alone ( •• £). incubated with (A.£) or without (0 •• ) 0.2 mM BSO for
various times, and assayed for cellular GSB (A) or for sensitivity to lysis
by glucose oxidase relative to untreated controls as in Figure 7 (B). LDSO
(control) = 1.79 ± 0.12 nmol of B202/min (N=3). Spontaneous release averaged
6.2 ± 0.7� (N=10). Recovery of both GSB content and resistance to H202 was
rapid in the absence of BSO (0) and totally inhibited by 0.2 mM BSO (A).
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induce resynthesis of GSH in the presence of BSO by incubation of
GSH-depleted cells with 1 mM y-glutamylcysteine or bis-Y-glutamyl­
cystine for 5 h were without success. Presumably. either these peptides
did not enter the cells or they were preferentially degraded by
Y-glutamylcyclotransferase and thus not available to GSH synthetase.
Effect of GSH Depletion on Tumor Cell Lysis by Granulocytes and
BOG-Activated Macrophages in the Presence of Phorbol Myristate Acetate
(PMA). We also evaluated the sensitivity of GSH-depleted tumor cells
to lysis by PMA-stimulated granulocytes and activated macrophages.
Figure 10 shows that 16 h incubation of both P388 (A) and P81S cells
(B) with 0.2 mM BSO resulted in a pronounced enhancement of
granulocyte-mediated cytolysis in the presence of PMA. Lysis of
BSO-treated and untreated tumor cells was inhibited by exogenous
catalase.
Similarly. incubation of P388 cells with BSO for 16 h markedly
augmented lysis by BCG-activated macrophages (Fig. 11). Cytolysis was
inhibited by catalase an average of 58 ± 7% (N=4).
Inhibition of Tumor Cell GR by BCNU. To further investigate the
role of the glutathione in tumor cell antioxidant defense. we sought a
means of inhibiting GR. thereby interupting the cyclic oxidation­
reduction of GSH. BCNU was recently reported to inhibit GR in human
erythrocytes without influencing the activity of any other enzyme
tested (Frischer and Ahmad 1977). We assayed GR in lysates of P81S
cells after exposing the intact cells to BCNU for 10 min (Fig. 12). GR
was SO� inhibited by 2.3 �g/ml (11 �M) BCNU and 95% inhibited by 100
�g/ml. Doses up to 300 �g/ml did not affect the activity of GPO or
so
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Figure 10. Effect of GSB depletion on the susceptibility of P388 cells
(A) and PS1S cells (B) to lysis by PMA-stimulated granulocytes. Prior
to assay� the tumor cells were incubated with (0) or without (.) 0.2 mM
BSO for 16 h. Catalase (3000 units/ml) inhibited lysis of both BSO­
treated (A) and untreated (A) cells. Pointssfre means of triplicates.
S.E. averaged 1.6�. Spontaneous release of Cr was <11�.
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Figure 11. Effect of 6SB depletion on the susceptibility
of P388 cells to lysis by BeG-activated macrophages in
the presence of 100 ng/ml of PMA. Prior to assay. the
tumor cells were incubated with (0) or without (.) 0.2 mM
BSO for 16 h. Points are means of trip�icates. S.E.averaged 1.4'. Spontaneous release of Cr was <12�.
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Figure 12. Effect of BCNU on the activity of GR, GPO, and
Catalase in P815 cells. The intact tumor cells were incubated
with the indicated doses of BCNU for 10 min at 37°C, washed,
lysed, and assayed. BU, Baudhuin units.
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catalase in the same cells (Fig. 12). Similar results were obtained
with P388 and TLX9 lymphomas (not shown).
Effect of BCNU on the Susceptibility of Tumor Cells to Oxidative
Cytolysis. Exposure of P81S mastocytoma cells to 100 �g/ml of BCNU for
10 min was nontoxic, as judged by exclusion of trypan blue and release
51
of Cr measured over a period of 18 h. However, BCNU treatment made
the tumor cells much more susceptible to lysis by small fluxes of H202•
For example, ·in the experiment illustrated in Figure 13, 18.7 times
less glucose oxidase was required to cause 50% specific release of SlCr
from P81S cells after pulsing them with BCNU. Similar results were
obtained with all six of the tumors studied; representative experiments
with P388 and J774 cells are also illustrated in Figure 13. Lysis of
the BCNU-treated tumors by glucose oxidase was abolished by exogenous
catalase, although inhibition of intracellular catalase with amino-
triazole had little effect (Fig. 13).
C. Discussion
In this section, the importance of tumor cell antioxidant defense
as a determinant of susceptibility to oxidative cytolysis is addressed.
The innate resistance of six murine tumor cell lines to lysis by
the H202-producing enzyme glucose oxidase correlated with the cellular
content of GSH, and not with the specific activities of catalase, GR,
or GPO. However, such a comparison of lysed cell preparations may not
accurately reflect conditions in the intact cell, especially as regards
compartmentalization.
Depletion of intracellular GSH was accomplished by two independent
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Figure 13. Effect of BCNU and aminotriazole on sensitivity of P388
(-), PS15 (--). and J774 (.•...) to lysis by fluxes of "2°2. SlCr­
release was measured from the tumor cells after a 4.5-h incubation with
dilutions of glucose oxidase. Before assay, the cells were treated with
vehicle alone (veh,.) or 100 �g/ml BCNU for 10 min (0), or incubated
with 25 or 50 mM aminotriazole (AT.A) for 45-60 min before and then
throughout the assay. Catalase (cat) (3.000 units/ml) abolished lysis
in all cases. as shown for J774 (x). Points are means of triplicates.
SEM averaged 2.0%.
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methods. First, de novo GSH biosynthesis was inhibited by incubation of
cells with BSO, a selective inhibitor of y-glutamylcysteine synthetase.
The rate of GSH depletion seen with inhibition of synthesis represents
a combination of GSH catabolism, efflux, and dilution by continuing
cell division. Incubation of P388 lymphoma or P815 mastocytoma cells
with 0.2 mM BSO resulted in a steady decline in GSH content, such that
50� reduction was reached by 4.5-5 h and 90� depletion by 15 h. As an
alternative approach to GSH depletion, we made use of the endogenous
enzyme GSH S-transferase by treatment of intact cells with exogenous
substrate (CDNB). Addition of 10 �M CDNB to P815 cells resulted in a
rapid consumption of GSH (approximately 70�). The inability to achieve
more extensive depletion of GSH with 30 �M CDNB may be due to its
propensity to inactivate the transferase which catalyzes its
conjugation with GSH (Pabst et al. 1974).
After 15-22 h of incubation with BSO, P81S and P388 cells
contained 2-8� of their initial GSH content and exhibited markedly
increased sensitivity to lysis by a flux of H202• These GSH-depleted
tumor cells were effectively lysed by dilutions of glucose oxidase and
numbers of PMA-stimulated granulocytes or activated macrophages which
were ineffectual against untreated tumors. Treatment of P815 cells with
10-30 �M CDNB for 15 min was equivalent to a 9-h incubation with BSO in
terms of the relative increase in sensitivity to lysis by H202 as well
as the extent of GSH depletion. The inclusion of 15 �M CDNB in the
4.5-h cytolysis assay, however, resulted in sensitization to H202-
mediated lysis beyond that obtained with BSO. Perhaps the combination
of GSH depletion and inhibition of GR by CDNB, reversible upon
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dilution. was responsible for this further enhanced sensitivity to
Recovery of tumor cell resistance to peroxide after BSO-induced
GSB depletion followed the same time course as resynthesis of cellular
GSB. Similarly. recovery of resistance to lysis by H202 after treatment
with CDNB was dependent upon de novo GSB synthesis and followed an
equivalent time course. The resynthesis of GSB to supernormal levels
subsequent to depletion by sulfhydryl-reactive compounds. such as was
observed here with CDNB. has been previously reported for rat duodenal
mucosa (Pisciotto and Graziano 1980). Tempory release of y-glutamyl­
cysteine synthetase from nonallosteric inhibition by GSB may playa
role in this phenomenon (Richman and Meister 1975).
Inhibition of tumor cell GR with BCNU was based on the work of
Frischer and Ahmad (1977) and Babson and Reed (1978). Incubation of
intact P815 cells with 100 �g/ml of BCNU for 10 min served to inhibit
GR by 95� without effect on catalase or GPO activities. Tumor cells in
which GR had been inhibited were markedly more susceptible to lysis by
B202• BCNU sensitized tumor cells to lysis by activated macrophages in
the presence of PMA or antitumor antibody. but not to allosensitized T
cells. nor to lysis by antibody plus complement (Nathan et al. 1981).
It has also been reported that GPO-deficient tumor cells. generated by
repeated passage of tumor cells in mice fed a selenium-deficient diet.
are substantially more sensitive to lysis by glucose oxidase and by
PMA-stimulated granulocytes and macrophages (Nathan et al. 1981).
Comparison of results obtained with BSO-induced GSB depletion with
those observed with inhibition of GR by BCNU yields informative
S7
differences. BCNU treatment of P388 results in greater sensitization to
H202 than does BCNU treatment of P81S (Nathan et al. 1981 and above)�
whereas the converse is true with GSH depletion. This is perhaps
related to the fact that of the two cell lines� P81S contains more GSH�
whereas P388 has more GR. In contrast to the results obtained with P8IS
and P388� a 9S� reduction in the GSH content of the TLX9 lymphoma does
not alter its susceptibility to lysis by glucose oxidase. In this
regard� it should be noted that GSH depletion sensitizes P81S and P388
cells to amounts of glucose oxidase which will effectively lyse
untreated TLX9 cells. Furthermore� of the three cell lines� TLX9
contains the most GR� inhibition of which with BCNU does impair its
antioxidant capabilities (Nathan et al. 1981). Thus� the intracellular
concentration of GSH appears not to be rate-limiting in the GSH redox
cycle of TLX9, even after a 9S% depletion. In addition� these tumor
cell lines may vary in their content of antioxidants other than GSH.
Finally� efforts to demonstrate enhanced macrophage-mediated antibody­
dependent cytotoxicity against GSH-depleted tumors, as had been
observed with BCNU-treated tumor cells (Nathan et al. 1981), were
without success (unpublished observations). The reasons for this
difference are not understood.
In erythrocytes, the relative importance of GPO and catalase for
the detoxification of H202 has been shown to depend upon the rate at
which H202 is added to the cells (Cohen and Hochstein 1961, 1963).
Similarly� we found the mode of peroxide delivery (as a bolus of pre­
formed H202 versus a flux of nascent H202) to be an important factor in
determining the antioxidant pathways a target cell might effectively
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employ to escape injury. In response to nascent H202, such as that
generated by glucose oxidase or leukocytes, the glutathione system, but
not catalase, played a major protective role. This may be attributed to
the ability of GPO, but not catalase, to detoxify lipid hydroperoxides
(Christophersen 1968) or to an affinity of GPO for H202 3 orders of
magnitude greater than that of catalase (Ogura 1955; Flohe and Brand
1969). When H202 was added as a bolus, however, both catalase and GSH
were able to function in a protective capacity, since sensitization was
seen only with a combination of GSH depletion and inhibition of
catalase. In contrast, it has recently been reported that lysis of
human erythrocytes by PMA-stimulated neutrophils can be enhanced by
inhibition of erythrocyte catalase with aminotriazole, as well as by
inhibition of GR with BCNU (the combination was not tested) (Weiss
1980). Furthermore, erythrocyte lysis was dependent upon methemoglobin
formation. Thus, conclusions concerning both the nature of cell­
mediated oxidative injury and the relative importance of target cell
antioxidant defenses based on studies with erythrocyte targets (Kellog
and Fridovich 1977; Borregaard and Kragballe 1980; Weiss and LoBuglio
1980; Weiss et al. 1980; Katz et al. 1980) cannot be generalized to
tumor cells without caution.
It should be noted that of the agents commonly used to alter
intracellular levels of GSH or its redox cycle, BSO is the least toxic
and the most specific. It does not react with cellular nucleophiles.
Conclusions as to the importance of GSH for cell division and continued
viability which are based on experiments in which cells are depleted of
GSH by exposure to such reactive agents as diethyl maleate, phenyl
S9
glyoxal. and 2-cyclohexenone. are weakened by questions of reagent
specificity. For murine tumor cells. as with erythrocytes (Kosower et
al. 1971), it appears that a temporary reduction in cellular GSB
content is compatible with normal viability unless an oxidant challenge
is generated concurrently. It is conceivable, therefore, that in
situations where potential oxidative injury can be directed to selected
target cells. such as by covalent linkage of glucose oxidase to tumor­
specific antibody (Philpott et al. 1973), nonspecific GSB depletion
might result in marked synergy without loss of selective toxicity.
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II. Lysis by Sulfhydryl-reactive Antineoplastics
A. Introduction
In the previous section. the importance of the GSH redox cycle in
tumor cell defense against oxidative injury. such as that inflicted by
cells of the host immune system or by incubation with glucose oxidase
plus glucose. was documented. In a variety of cell types. GSB plays a
role in protection against toxic electrophiles by thioether formation.
It was conceivable. therefore. that tumor cell GSH might effectively
detoxify and thus limit the effectiveness of sulfhydryl-reactive
antineoplastic agents. To evaluate this possibility. the role of GSB
and its synthesis in tumor cell defense against a class of sulfhydryl­
reactive antitumor agents. the sesquiterpene lactones (SLs). was
examined.
SLs are among the natural products that have attracted attention
recently as prototypes for the development of novel chemotherapeutic
agents (Kupchan 1970. 1974; Rodriguez et al. 1976; Douros and Suffness
1978; Cassady and Suffness 1980). Some SLs inhibit cell growth in
vitro. and at higher concentrations. lead to cell death (Lee et al.
1971; Rosowsky et al. 1974; Hladon et al. 1975; Woynarowski and Konopa
1981; Dupuis and Brisson 1976). High reactivity towards sulfhydryl
groups in aqueous buffer is a characteristic feature of SLs (Kupchan et
al. 1970. 1971; Lee et al. 1977; Picman et al. 1979). and has led to
the hypothesis that their antitumor activity is the result of
S-alkylation of growth-regulatory or otherwise vital macromolecules
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(Kupchan et al. 1971; Kupchan 1974, 1976; Fujita and Nagao 1977).
Several sulfhydryl-dependent enzymes have been shown to be inhibited by
these agents (Banson et al. 1970; Smith et al. 1972; Lee et al. 1977;
Ball et al. 1978). Nonetheless, the cellular targets relevant to their
antitumor activity in vitro or in vivo have not been identified.
Furthermore, it has not been reported whether SLs are reactive towards
sulfhydryl groups in intact cells.
In this section the results of studies with four SLs that are
active in vivo are presented (vernolepin. helenalin. elephantopin. and
eriofertopin, Fig. 14). Data are provided correlating sulfhydryl
reactivity with a role for tumor cell GSB as a determinant of cytolysis
by an additional seven unrelated chemotherapeutic compounds.
B. Results
Depletion of Tumor Cell GSB by SLs. The possible interaction
of cellular GSB with SLs was first evaluated. Incubation of P81S
mastocytoma cells with vernolepin. helenalin. elephantopin. or
eriofertopin for 1 h resulted in 70-97� depletion of GSB (Table IV).
The time course and dose response of GSB depletion by helenalin was
examined in greater detail in the experiments illustrated in Figure IS.
Cells were incubated with a range of concentrations of helenalin with
or without 0.2 mM BSO. thus allowing for the observation of effects
with and without ongoing GSB synthesis. Depletion of GSB by incubation
of P81S cells with 2S �g/ml of helenalin was both rapid (90� loss
within IS min) and persistent (up to 7 h of coincubation) (Fig. ISA).
Incubation of cells with 1 �g/ml of helenalin did not result in
oo
Vernolepin
o
\
o
Elephantopin
o
CH2
Helenalin
HO.,
o
Eriofertopin
Figure 14. Structures of the sesquiterpene lactones
studied.
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Table IV
Effect of Cytotoxic SLs on GSH Content of P815 Cells
SL
% GSH
•
f,ls/ml remaining (N)
10 6.7 ± 2.7 (5 )
25 2.8 ± 0.5 (2)
5 41 ± 6.8 (2)
10 23 ± 1.2 (3 )
25 5.7 ± 1.6 (3 )
5 39 ± 2.9 (4)
15 12 ± 0.2 (2)
50 29 ± 3.6 (4)
Vernolepin
Helenalin
Elephantopin
Eriofertopin
•
P815 cells were incubated in a-Mml, 5% horse serum with the
indicated concentrations of sesquiterpene lactones for 1 h.
Data are from 10 experiments with initial GSH = 29.6 nmoll
mg of protein.
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Figure 15. Time course and dose response of GSH depletion by
helenalin in the absence (A) and presence (B) of BSO. P81S cells were
incubated with helenalin at 1 flg/ml (A), 5 Jlg/ml (!), 10 Jlg/ml (0), 25
Jlg/ml (.), or no helenalin (x). In panel B, the incubation medium also
contained 0.2 mM BSO. Data are from five experiments with initial 6SH
levels of 28.1 ± 6.3 nmol/mg of protein.
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detectable GSH depletion. However. the rate of GSH depletion upon
incubation with 1 �g/ml of helenalin plus BSO exceeded that observed
with BSO alone (Fig. 15B). By inference. 1 �g/ml of helenalin must
react with a substantial portion of intracellular GSH. and rapid
resynthesis. if unimpeded. maintains GSH content at normal levels.
Similarly. the recovery of GSH levels observed with 5 �g/ml of
helenalin was abolished by the inclusion of BSO (Fig. 15. closed
triangles). By examination of the medium after incubation of cells with
helenalin. it was determined that depletion of GSH was not due to its
release from the cells (not shown).
Effect of BSO on the Lysis of Tumor Cells by SLs. The sensitivity
51
of Cr-labeled tumor cells to lysis by SLs was first evaluated by an
18-h coincubation. Figure 16 illustrates one such experiment in which
the lysis of P815 cells by helanalin in the presence or absence of 0.2
mM BSO was measured. Incubation of tumor cells with BSO alone was
nontoxic. However. cytolysis by helenalin was greatly enhanced:
nonlytic concentrations of helenalin resulted in near-complete lysis
when BSO was included (Fig. 16). In Figure 16. BSO reduced the LDSO for
helenalin by a factor of 4.7. The effect of BSO on the sensitivity of
four tumor cell lines to lysis by SLs is documented in Table V. In each
experiment. a range of SL concentrations was tested and the LD50 was
calculated as in Figure 16. In all cases. the presence of BSO reduced
the LDSO manyfold. BSO provided the most dramatic synergy with
vernolepin. leading to an approximately 20-fold decrease in the LDSO
for P81S.
It is of interest to note that for these tumors. the rank order of
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Figure 16. Effect of BSO on the sensitivity of P815 cells
to lysis by helenalin. 51Cr release was measured after an
18-h incubation with the indicated concentrations of
helenalin in the absence (0) or presence (e) of 0.2 mM BSO.
Points are means of triplicate determinations. S.E.
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averaged 2.4�. Spontaneous release of Cr label was
22�.
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Table V
Effect of BSO on Sensitivity of Tumor Cells to Lysis by SLs
BSO-induced
D relative increase
SL
LDSO. J,lg/ml in sensi�iIity (N)Tumor (J,lM) to lys1S
P81S Vernolepin 21 ± 13 20 ± 8.3 (13)
(7S)
P81S Helenalin 12 ± 3.8 6.4 ± 1.6 (4)
(47)
P81S Elephantopin 28 ± 4.5 S.6 ± 2.S (4)
(79)
P81S Eriofertopin 68 ± 24 6.8 ± 1.8 (S)
(195 )
YAC Vernolepin 4.6 ± 2.0 8.9 ± 2.4 (4)
(17)
TLX9 Vernolepin 16 ± 7.4 19 ± 10 (4)
(S9 )
1774 Vernolepin 47 ± 16 34 ± 18 (3 )
(169)
OSI
Cr-Iabeled tumor cells were incubated for 18 h with the indicated
SLs and LDSO values were calculated by interpolation from curves like
those in Figure 16. Average spontaneous SICr release in the presence
and absence of BSO. respectively. for the four tumors: P81S. 26.6±4.4.
2S.7±4.3� (N=26); YAC. 21.3±4.6. 20.0±3.0% (N=4); TLX9. 21.8±1.1. 21.0
±2.3� (N=4)j 1774. 20.1±1.7. 19.9±2.4� (N=3).
*
The LDSO in the absence of BSO divided by the LDSO in the presence
of 0.2 mM BSO represents the relative increase in sensitivity to lysis
by the various SLs.
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resistance to lysis by vernolepin (J774 > P81S > TLX9 > YAC) does not
correspond to GSB content (J774 > YAC > P81S > TLX9) (Nathan et al.
1981). Furthermore, incubation of P81S cells with 10 �g/ml of
vernolepin for 1 h before the 18-h assay did not result in increased
cytolysis (not shown), in spite of substantial depletion of GSB (>90�
in Table IV). Thus, in contrast to the importance of GSB resynthesis in
p�otecting tumor cells upon exposure to SLs, GSB content prior to
exposure to these agents did not influence subsequent lysis.
The synergistic interaction between BSO and vernolepin was further
analyzed by considering the kinetics of onset and reversal of their
effects. For this, exposure of cells to vernolepin was limited to a I-h
pulse, followed by an 18-h incubation in its absence, at which time
lysis was determined. Figure 17 illustrates the results obtained in one
of three such experiments in which lysis in the absence of BSO (open
triangles, LDSO = 63 �g/ml) was compared to lysis observed when BSO was
present 30 min before and during the I-h vernolepin incubation (open
circles, LDSO = 7.3 �g/ml); during this time as well as the subsequent
18-h incubation (close circles, LDSO = 6.8 �g/ml); or during the 18-h
incubation only (close triangles, LDSO = 13.8 �g/ml). Thus, addition of
BSO need not coincide with but can immediately follow exposure to
vernolepin for markedly enhanced cytolysis to result.
Time Course and Recovery From the Effects of Vernolepin and BSO.
Figure 18 illustrates the correlation between GSB resynthesis and loss
of tumor cell sensitivity to the synergistic effect of BSO added after
a I-h pulse of vernolepin. Recovery of GSB content upon subsequent
incubation was rapid, reaching control levels by 3.5 h. Recovery of GSB
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Figure 17. Effect of BSO on sensitivity of P81S cells to
lysis at 18 h after a 1-h incubation with vernolepin. Cells
were pulsed with the indicated concentrations of veJfolepin
for 1 h and then incubated for 18 h, at which time Cr
release was measured. BSO was present at 0.2 mM 30 min before
and during the I-h pulse (0), during this time as well as the
subsequent 18-h incubation (.), during the 18-h incubation
only (i), or never (A). Points are means of triplicate
determinations. S.E. averaged 1.2%. Spontaneous release
was 20-22�.
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Figure 18. Correlation between the rate of GSB resynthesis
after a 1-h incubation with vernolepin and the loss over
time of synergistic cytolysis when BSO was added after the
vernolepin pulse. In the cytolysis assay, cells were
pulsed with 10 �g/ml of v,rno�fpin for 1 h and then incu­
bated for 18 h at which time Cr release was determined.
BSO was present in the medium for the indicated time spans
(�), i.e. either it was present during the vernolepin
pulse and then washed out or it was added at the indicated
times after the pulse treatment for the remainder of the
18-h incubation. S.E. averaged 1.3� for triplicates. Spont­
aneous release was <28�. Percent specific release from
cells pulsed with vernolepin but never incubated with BSO
was <3�. Unlabeled P81S cells were similarly incubated with
10 �g/ml of vernolepin for 1 h, washed, incubated in the
presence (A) or absence (A) of BSO for the indicated times,
and then assayed for GSB content. Untreated cells contained
24.4 ± 2.4 nmol GSB/mg of protein (N=4).
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content could be inhibited by BSO, indicating that de novo resynthesis
was occuring. A 1.S-h delay in the addition of BSO to cells previously
pulsed for 1 h with 10 �g/ml of vernolepin allowed for resynthesis of
GSB to approximately 60� of control, and resulted in roughly a 60�
decrease in enhancement of cytolysis, compared to the addition of BSO
Urumediately after the vernolepin pulse. The marked cytolysis observed
by treatment of cells with 10 �g/ml of vernolepin followed by an 18-h
incubation with BSO was not prevented by the addition of up to 7 mM GSB
to the medium shortly after the start of the 18-h incubation (not
shown).
The reversal of BSO inhibition of Y-glutamylcysteine synthetase is
not immediate (see Table III in Section I of Results). We therefore
compared the time course of recovery from the effects of BSO on
cellular GSB content and on sensitivity to vernolepin-mediated cyto­
lysis. In the experiment illustrated in Figure 19, P81S cells were
incubated with BSO for 1 h, washed, incubated for various additional
times, and then assayed both for GSB content and for susceptibility to
lysis by vernolepin. Gradual recovery of GSB synthesis was evident
within 2 to 3 h of the removal of BSO. A net increase in GSB content
did not occur until 4 or more h of incubation in the absence of BSO
(Fig. 19A). Similarly, approximately 3 h after a I-h incubation with
BSO, cells began to recover their resistance to the cytolytic effect of
vernolepin (Fig. 19B). Thus, augmentation by BSO of susceptibility to
lysis by vernolepin disappeared just as the tumor cells regained their
capacity to synthesize GSB. Addition of cycloheximide (10 �g/ml) after
removal of BSO did not inhibit recovery, indicating that synthesis of
72
0'1
c::
·c
·0
E
OJ
\...
OJ
c::
0
s:
-
.E
:J
0'1
-
c::
OJ
U
\...
OJ
a...
80
OJ
en
0
OJ
OJ
\...
U
i.;:
·u
OJ
a.
en
-
c::
OJ
U
\...
OJ
a...
B
.- - -.- - - - - - -.- - __--.
o
0 2 4 6
Hours after SSO
8
Figure 19. Time course of recovery from the
effects of BSO. (A) P81S cells were incubated with
0.2 mM BSO for 1 h, washed, and then incubated in
the presence (�) or absence (A) of BSO. At various
times GSB content was determined and is here
expressed as percent GSB remaining (initial level,
24.2 nmol/mg of protein). (B) Cells were incubated
for 1 h in the presence (0) or absence (.) of BSO,
washed, and then incubated in its absence. !t the
indicated times, vernolepin (20 �g/ml) and Cr
were added for an additional 1 h, cells were
washed, and then incubated for 18 h, at which time
specific release was determined. Spontaneous
release was 20'. S.E. averaged 1�.
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new Y-glutamylcysteine synthetase was not required in order to reverse
the effects of BSO (not shown).
GSB Depletion by Other Antitumor Agents and the Effect of BSO on
Cytolysis by These Agents. Many antitumor agents recently derived from
plants. in addition to the cytotoxic SLs. have been shown to possess
high reactivity toward sulfhydryl groups (Hanson et al. 1970; Kupchan
and Tsou 1973; Lillehaug et al. 1973; Kupchan and Schubert 1974;
Kupchan and Lacadie 1975; Kupchan 1976; Fujita and Nagao 1977).
Jatrophone. one such compound. was isolated in 1970 from a plant used
in Costa Rica for the treatment of cancer. Incubation of P81S cells
with jatrophone resulted in marked depletion of GSB. with only 11% of
initial levels remaining after a I-h incubation with 15 �g/ml (Table
VI). P81S cells were incubated for 18 h with various concentrations
of jatrophone in the presence or absence of BSO. at which time lysis
was measured. One of four such experiments is shown in Figure 20.
Inhibition of GSB synthesis resulted in a 21.3 ± 7-fold increase in
sensitivity to lysis. relative to cells allowed to synthesize GSB
(Table VII). In contrast. prior depletion of GSB by pulsing cells with
10 �g/ml of vernolepin for 1 h did not sensitize the cells to the lytic
effects of jatrophone (not shown).
In a similar manner. six other antitumor agents chosen from three
major classes of antineoplastics (alkylating agents. anti-metabolites.
and natural products) were studied. The effects of these compounds on
the GSB content of P81S cells. using a 1-h incubation at concentrations
that would be lytic in an 18-h assay. are documented in Table VI. Of
these. only BCNU was able significantly to reduce the GSB content of
Table VI
Effect of Various Antineoplastic Agents on GSH
Content of P815 Cells
Agent
% GSH
•
Jig/ml remaining (N)
100 96 ± 10 (2)
300 101 ± 18 (3 )
5 91 ± 4.7 (2)
10 96 ± 0.5 (3 )
100 82 ± 6.0 (2 )
300 81 ± 14 (2)
50 88 ± 4.6 (3 )
50 13 ± 2.9 (2)
100 10 ± 1.6 (2)
200 20 ± 9.3 (2)
5 38 ± 2.7 (3 )
15 11 ± 1.5 (2 )
Doxorubicin
Mitomycin C
Vinblastine
Ara-C
Maytansine
BCNU
Jatrophone
•
Data are from 5 experiments with initial GSH = 25.4 ±
10.5 nmol/mg of protein. Cells were incubated with agents
at the indicated concentrations for 1 h at 37oC.
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Figure 20. Effect of BSO on sensitivity of P81S cells to lysis
51
by jatrophone. Cr release was measured after an 18-h
incubation with the indicated concentrations of jatrophone in the
absence (0) or presence (.) of 0.2 mM BSO. S.E. averaged 1.9� for
triplicates. Spontaneous release was <26�.
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Table VII
Effect of BSO on Sensitivity of P815 Cells to Lysis by
Various Antineoplastic Agents
LDSO' BSO-induced relative•
flg/ml increase in
Agent (flM) sensitivity to lysis (N)
Doxorubicin 74 ± 14 1.2 ± 0.8 (3 )
(127)
Mitomycin C 5.8 ± 0.6 0.99 ± 0.06 (2)
(17)
Vinblastine 30 ± 5.0 0.74 ± 0.11 (2)
(33 )
Ara-C 4.9 ± 0.6 0.71 ± 0.10 (2)
(18)
Maytansine 36 ± 4.0 0.91 ± 0.09 (3 )
(52 )
BCNU 37 ± 7.0 1.17 ± 0.05 (3 )
(174)
Jatrophone 6.8 ± 1.0 21.3 ± 7.0 (4)
(22 )
•
LD50 values were calculated by interpolation from dose-response
curves. For Ara-C, LD2S is reported. S.E. averaged 2.4% for all
agents. Average spontaneous 51Cr release in the absence or
presence of BSO, respectively, was 23.9 ± 4.2 and 22.3 ± 4.1�
(N=19).
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the cells. However, unlike jatrophone or SLs, cytolysis by BCNU after
an 18-h incubation was not affected by the presence of BSO (Table VII).
The lack of an effect of BSO on cytolysis by the other five agents
correlated with their inability to deplete cellular GSB (Tables VI and
VII).
C. Discussion
Incubation of P81S mastocytoma cells with any of the four SLs
studied (vernolepin, helenalin, elephantopin, and eriofertopin)
resulted in rapid, dose-dependent depletion of GSB, presumably via
adduct formation. Comparison of the rate of GSB depletion by low
concentrations of helenalin (1-S pg/ml) in the presence of BSO, a
nontoxic and selective inhibitor of Y-glutamylcysteine synthetase,
with that observed with BSO alone or helenalin alone, suggests that a
compensatory increase in the rate of GSB synthesis is an early cellular
response to these agents.
Extensive GSH depletion of P81S cells by prolonged incubation with
BSO was without effect on their viability or even their growth (Section
I of Results). In striking contrast, inhibition of GSB synthesis during
an 18-h incubation with SLs markedly enhanced the lysis of the same
cells. A potent synergistic effect of BSO on cytolysis by vernolepin
was also observed with each of the other murine tumors tested (YAC,
TLX9, and J774).
To characterize further the role of GSB synthetic capacity as a
determinant of tumor cell susceptibility to cytolysis by SLs, PS1S
cells were pulsed with vernolepin for 1 h, washed, and assayed for SlCr
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release after an additional 18-h incubation in the absence of
vernolepin. Addition of BSO to cells promptly after the vernolepin
pulse resulted in enhanced lysis. However. as the interval lengthened
between the vernolepin pulse and exposure to BSO. the tumor cells
rapidly lost this enhanced susceptibility to lysis. with a time course
that correlated with the restoration of GSH levels.
BSO probably does not inhibit GSB synthesis by intact cells
immediately after it is added to the extracellular medium. This
substrate analog must first enter the cell (Griffith 1981a) and be
phosphorylated by its target enzyme. y-glutamylcysteine synthetase
(Griffith 1981b. 1982). More cytolysis was evident if BSO was present
not only during the I-h vernolepin treatment. but 30 min before it as
well (96� vs. 81%, p <0.05; Fig. 18). Thus. P81S cells appear to be
more sensitive to the lytic effects of vernolepin if their GSB
synthetic capacity is already inhibited at the onset of vernolepin
exposure.
Another aspect of BSO-induced inhibition of GSB synthesis relevant
to this analysis is its delayed reversibility. After a I-h pulse with
BSO. GSH synthetic capacity sufficient to replenish cellular GSB was
not manifest until 4-5 h of further incubation. Likewise, if a pulse
with BSO preceded treatment with vernolepin. a synergistic effect on
cytolysis was only seen with the interval between exposures to the two
agents was <4-5 h.
The effect of BSO on cytolysis by seven additional antitumor
agents was evaluated. and compared to the sulfhydryl-reactivity of the
same compounds. With one exception, the relative ability of the
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cytotoxic agents to deplete GSH correlated with its ability to interact
sy�ergistically with BSO resulting in increased cytolysis. Five of the
compounds tested, including the ansa macrolide maytansine, did not
significantly affect cellular GSH content and did not cause increas�d
lysis in the presence of BSO. In contrast, the ability of BCNU to
deplete GSH, observed by us and others (Babson et al. 1981; McConnell
et al. 1979), did not translate into increased lysis in the presence of
BSO. One explanation might be that depletion of GSH by BCNU is of no
relevance to either its mechanism of injury of the biochemistry of
cellular response and repair.
Cytotoxicity of doxorubicin and mitomycin C in the presence of
oxygen, such as in these experiments, should be distinguished from
their activity against hypoxic cells (Teicher et al. 1981). Under
hypoxic conditions, these quinone-containing drugs are believed to
undergo reductive metabolic activation to highly reactive quinone
methide alkylating agents (Moore 1977; Kennedy et al. 1980b, 1982). It
is possible that the quinone methide metabolites of doxorubicin and
mitomycin C are detoxified by GSH in a manner analogous to the SLs and
jatrophone. Thus, BSO might augment the cytolytic activity of these
agents against hypoxic tumor cells while having no effect on their
toxicity to oxygenated cells.
As a determinant of cytolytic susceptibility, the importance of
functional y-glutamylcysteine synthetase during and after exposure to
SLs surely reflects a critical requirement for GSH synthesis at those
times. In contrast, GSH content prior to incubation of cells with
vernolepin or jatrophone affords no protection. One possible
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interpretation is that the amount of vernolepin consumed by reaction
with intracellular GSH at the onset of drug exposure is not significant
relative to the amount of vernolepin added to achieve lysis.
One can envisage a number of explanations for the importance of
GSH in SL-mediated cytolysis. SLs did not deplete whole-cell GSH to an
extent greater than that obtained by prolonged incubation with BSO,
which was nontoxic (Section I of Results). However, it is possible that
the GSH of particular organelles, such as mitochondria or the nucleus,
was depleted more by SLs than by BSO, with toxic consequences.
Alternatively, GSH might serve to detoxify SLs, either prior to the
alkylation of target molecules, or by preventing cross-linking through
reaction with a second sulfhydryl-reactive site, in analogy with the
biscysteine adducts of helenalin, vernolepin, and elephantopin (Kupchan
et al. 1970; Picman et al. 1979). A role for GSH in the restoration of
critical sulfhydryl groups subsequent to alkylation should also be
considered. In the next section, data implicating a role for oxidant
injury as the basis of vernolepin-mediated toxicity will be presented.
Thus, a critical role for GSH and its redox cycle in antioxidant
defense is suggested. Finally, the cardinal issue, whether inhibition
of tumor cell GSH synthesis will enhance the therapeutic efficacy of
SLs and similar sulfhydryl-reactive agents in tumor-bearing animals,
is under study. Preliminary findings will be presented in the next
section.
81
III. Cystine-Dependence of Vernolepin-mediated Cytolysis:
A Role for Oxidative Injury
A. Introduction
In the previous section, inhibition of GSH synthesis by BSO either
during a coincubation with SLs or immediately after a pulse exposure to
venolepin markedly augmented cytolysis. As a way of confirming these
findings without the use of drugs, we sought to reproduce the
synergistic effect of BSO by withholding cystine. Reed and co-workers
have reported that two murine lymphoma cell lines (L1210 and LS178Y)
require exogenous cystine as a source of cysteine for GSH synthesis,
whereas isolated rat hepatocytes are able to utilize the sulfur of
methionine for cysteine biosynthesis via the cystathionine trans­
sulfuration pathway (Beatty and Reed 1980; Brodie et al. 1981, 1982).
In this section, the dependence of P81S cells on exogenous cystine for
GSH synthesis is first examined. Then, cytolysis of P81S cells
resulting from a 1 h pulse with vernolepin followed by an 18-20 h
incubation in medium with or without cystine is evaluated. Contrary to
expectation, vernolepin-mediated cytolysis demonstrated a requirement
for exogenous cystine. Our experimental approach to this phenomenon is
detailed in the remainder of this section.
B. Results
GSH Synthesis in P81S Cells is Dependent upon Exogenous Cystine.
To evaluate the dependence of GSH synthesis in P81S cells on the
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availability of cystine, medium specifically lacking in L-cystine was
prepared (Eagle's MEM minus cystine). P81S cells were incubated with 2S
pg/ml of vernolepin for 1 h in cystine-free medium, resulting in >95�
depletion of 68B, washed, and then incubated with and without cystine.
The time course of 68B resynthesis in the presence of cystine (0.09 mM)
is illustrated in Figure 21. 68B content was restored to 90% of control
within S h. No significant 68B synthesis was observed in cystine-free
medium or in medium containing cystine and B80. The dose-response of
cystine-mediated 68B resynthesis is presented in Figure 22. A log­
linear relationship is evident for cystine between 9 and 270 pM.
Cystine at 2.7 pM was insufficient to provide for detectable G8B
synthesis by 3 h.
Effect of Cystine on Vernolepin-mediated Lysis of P81S Cells.
With the knowledge that P81S cells require exogenous cystine for G8B
synthesis, we expected that vernolepin-mediated lysis of cells in
cystine-free medium would mimic that observed in regular medium in the
presence of B80. To our surprise. cytolysis, measured 18-20 h after a
I-h vernolepin pulse. was strongly dependent upon the presence of
cystine. In one such experiment. illustrated in Figure 23, P81S cells
were pulsed for 1 h with 0, SO, or 250 pg/ml of vernolepin in cystine­
free medium, washed, and then incubated for 18 h with various concen­
trations of cystine, with or without B80, at which time lysis was
measured. There was no significant lysis in the absence of cystine. For
cells pulsed with 250 pg/ml of vernolepin, significant lysis was
observed with as little as 9 � cystine with B80 present. Without B80,
equivalent lysis of these cells occurred with 90 pM cystine.
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Figure 21. Effect of cystine on resynthesis of GSH after
depletion by vernolepin: time course. P81S cells were
incubated for 1 h in cystine-free MEM� S� horse serum with
2S �g/ml of vernolepin� washed� and then incubated in the
presence (.�A) or absence (0) of L-cystine (0.09 mM)� in
the presence (A) or absence (.�o) of BSO (0.2 mM). At the
indicated times GSH content was determined. Data from two
experiments are presented. Untreated cells contained 16.1
± 1.8 nmol/mg of protein.
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Figure 22. Effect of cystine on resynthesis of GSH after
depletion by vernolepin: dose-response. P81S cells were
incubated for 1 h in cystine-free MEM, S� horse serum with
25 �g/ml of vernolepin, washed, and then incubated with the
indicated concentrations of L-cystine for 1 h (.) or 3 h
(0), at which time GSH content was determined. Data from two
experiments are presented. Untreated cells contained 16.1 ±
1.8 nmol GSH/mg of protein.
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Figure 23. Effect of cystine on vernolepin-mediated lysis of
P81S cells. P81S cells were pulsed for 1 h in cystine-free
MEM, S� horse serum with 50 �g/ml (�,A) or 250 �g/ml (0,.) of
vernolepin, washed, and then incubated for 18 h with the indi­
cated concentrations of cystine, with (.,A) or without (o,�)
BSO (0.2 mM), at which time release of label was determined.
Points are means of triplicates. S.E. averaged 1�. Spontaneous
release after 18 h with the indicated concentrations of
cystine from cells not exposed to venolepin was 18-20%.
8S
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Incubation of P81S cells in leucine- or tryptophan-free medium
after the vernolepin pulse did not abolish cytolysis (Table VIII).
Similarly, the addition of 2S pg/ml of cycloheximide to the post­
vernolepin incubation in cystine-containing medium did not inhibit
lysis. Thus, this cytolytic requirement for cystine is not shared by
other essential amino acids, nor does it reflect a need for protein
synthesis.
Role of Oxidative Injury in Lysis of P81S Cells by Vernolepin.
A number of investigators have described cysteine-associated toxicity,
both in vivo and in vitro. The addition of cysteine to mammalian cell
cultures was cytotoxic (Nishiuch et al. 1976) in a manner inhibitable
by catalase (Higuchi 1963). Carlsson et al. (1979) have found the
bactericidal effect of cysteine under aerobic conditions to be enhanced
by superoxide dismutase and abolished by catalase or metal ion
chelating agents. They further demonstrated metal-catalyzed production
of B202 by cysteine, as have Cavallini et al. (1968). The generation of
superoxide anion as a consequence of thiol autoxidation has been
reported by Misra (1974).
The remainder of this section will be organized about the hypo­
thesis that intracellular cysteine, arising in our case from the uptake
and reduction of exogenous cystine, generates H202 intracellularly as
it autoxidizes. Such an oxidant stress may be easily managed by a
GSB-containing cell, though fatal to a severely GSB-depleted cell.
Recall from Section I of Results that depletion of GSB by
prolonged incubation with BSO or exposure to CDNB markedly enhanced
susceptibility of P81S cells to oxidant injury. It was therefore of
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Table VIII
Vernolepin-mediated Lysis of P81S cells: Role of Exogenous *
Cystine. Leucine. or Tryptophan. and Effect of Cycloheximide
Percent s�ecific release at 20 h
Incubation conditions
vernolepin (l-h pulse)
BSO SO f,lg/ml 150 f,lg/ml
Complete medium
D
3 22
+ 17 71
- cystine -4 0
+ -2 4
- leucine 1 31
+ 32 76
- tryptophan 1 24
+ 24 78
+ cycloheximide� 0 28
+ 20 74
*P815 cells were labeled with SICr for 1 h with vernolepin in MEM
lacking cystine. leucine. and tryptophan (plus 5% horse serum).
washed. and then incubated for 20 h in the indicated media. with
or without BSO (0.2 mM). Under any of the 20-h incubation conditions.
there was noS!ysis of cells which had not been exposed to vernolepin.
Spontaneous Cr release in complete medium was 24%. Data are means
of duplicates (S.E. averaged 1.9%).
IComplete medium is Eagle's MEM. 5% horse serum. with cystine.
leucine. and tryptophan present at 0.09. 0.4. and 0.05 MM.
respectively.
-It
25 f,lg/ml
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interest to evaluate the effect of vernolepin on lysis of P815 cells by
a flux of H202 generated by the addition of glucose oxidase to the
glucose-containing medium. In one such experiment (Fig. 24A), H202-
mediated lysis at 5 h was markedly enhanced in the presence of 10 �g/ml
of vernolepin. Figure 24B illustrates the dose-response of vernolepin­
induced sensitization to glucose oxidase-mediated cytolysis. A >6.5-
fold increase in susceptibility to lysis by H202 was achieved with
20 �g/ml of vernolepin (Fig. 24B). Addition of BSO together with the
indicated concentrations of vernolepin served to enhance even further
the oxidative lysis of these cells (Fig. 24B), presumably due to more
extensive GSH depletion (see Fig. 15). Inclusion of BSO alone was
without effect (Fig. 24A). Cytolysis of vernolepin-treated cells by the
addition of cysteine was also observed and was inhibited by catalase.
(not shown).
Near-complete GSH depletion does not automatically result in
cytolysis in cystine-containing media. P815 cells in u-MEM will remain
viable and continue to divide in the presence of BSO for at least 3
weeks. Yet, after 24 h of incubation with BSO, GSH content is
undetectable by our assay method (less than 3-5� of control).
Vernolepin exposure which results in GSH depletion on a whole-cell
basis equivalent to prolonged incubation with BSO leads to cytolysis in
the presence of cystine. One possible explanation for this difference
is that gradual GSB depletion, such as with BSO, allows for cellular
adaptation so that intracellular cysteine autoxidation does not occur.
If this were the case, one might expect that after prolonged BSO
incubation, cells would be refractory to cytolysis by a pulse exposure
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Figure 24. Effect of vernolepin on sensitivity of P81S cells to
lysis by a flux of H202• SICr release was measured after a S-h
incubation with dilutions with glucose oxidase. (A) Present
during the cytolysis assay was 10 �g/ml of vernolepin (�), 0.2
mM BSO (e), or neither (0). Points are means of triplicates.
S.E. averaged 1.4�. Spontaneous release of SICr was <10'. (B)
Vernolepin at the indicated concentrations was included in the
S-h incubation with glucose oxidase in the presence (e) or
absence (0) of BSO. LDSO were calculated by interpolation from
curves like those in panel A, and the relative increase in
sensitivity to lysis (LDSO(control)/LDSO(treated» was
determined. LDSO(control) = 0.79 nmol of H202/min. Spontaneous
release averaged 13.1 ± 0.8' (N=8). Addition of vernolepin at
concentrations greater that those indicated resulted in
significantly elevated spontaneous releases (i.e. lysis in the
absence of glucose oxidase).
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to vernolepin. As illustrated in Table IX, the opposite proved to be
the case. Incubation of P81S cells with BSO for 72 h prior to
vernolepin exposure resulted in substantially greater cytolysis
compared to cells not incubated with BSO. Recall from Section I of
Results (Fig. 8) that pre-depletion of GSB by incubation with BSO
abolished the ability of CDNB to further sensitize the cells to
oxidative cytolysis. Thus, either vernolepin gains access to a BSO­
resistant pool of GSB, quantitatively small though crucial for cell
survival, or cellular GSB is not its only relevant target.
Inhibition of GR or Catalase Enhances Lysis of P81S Cells by
Vernolepin. Inhibition of tumor cell antioxidant defenses, in
particular the GSB redox cycle, markedly augments oxidative cytolysis
(Section I of Results). The hypothesis that vernolepin-mediated
cytolysis is due to the intracellular generation of B202 from the
autoxidation of cysteine suggests that interference with tumor cell
antioxidant pathways, beyond the GSB depletion brought about by
vernolepin, might increase cytolysis even further.
Table X presents data from 2 experiments in which P81S cells were
pulsed with vernolepin, with or without aminotriazole, for 1 h in
cystine-free medium. Treatment with BCNU was for IS min, either prior
to or during the end of the vernolepin pulse. Cells were then washed,
and incubated for 20 h with or without cystine, aminotriazole, or BSO,
at which time lysis was determined. Cells exposed to BCNU alone (10
�g/ml) were not lysed. The combination of BCNU and vernolepin was
especially potent, resulting in near-complete cytolysis at doses of
vernolepin which were minimally toxic without BeNU. This synergistic
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Table IX
Effect of Prior Incubation with BSO on Lysis of P81s Cells
by Vernolepin With and Without Cystine
•
Treatment
72 h prior
incubation
with BSO
I-h pulse
with
vernolepin
Percent specific release at 20 hI
+ cystine13- cystine
BSO.\t
+
[22]
-5
-5
-4
o
50
+
16
22
3
53
+
[20]
-1
-2
-2
+ o
+ 50
+
32
45
87
87
•
P81S cells were incubated with or without BSO (0.2 mM) for 72 h
priors!o vernolepin exposure, as indicated. Cells were labeled
with Cr during the I-h pulse with vernolepin.
DRelease of slCr from labeled cells was determined after a
20-h incubation under various conditions, as indicated.
Spontaneous release values for the two cell populations are
shown in the brackets. S.E. averaged 1.7% for duplicates.
-1+0•2 mM
130•09 mM
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Table X
*
Effect of BCNU and AT on Lysis of P815 Cells by Vernolepin
Percent specific release at 20 h
I-h pulse without
cystine
with cystine
vernolepin AT#
(lJ.g/ml) (mM)
-AT +AT
BCNU
(lJ.g/ml) -BSO +BSO -BSO +BSO -BSO +BSO
Experiment 1
100 0
0 0
100 0
Experiment 2
50 0
0 50
50 50
50 0
o -4 -3 -1 62
10 7 5 2 2
10 -2 3 92 90
o -10 -14 -11 6 -7 40
o 6 1 -1 -1 5 4
o -13 -10 -11 6 -4 39
10 o -2 9 85 22 94
*P815 cells were labeled with 51Cr for 1 h in cystine-free medium with or
without vernolepin and AT, as indicated. Treatment with BCNU was for 15 min,
either prior to (experiment 1) or during the last 15 min of (experiment 2)
the I-h vernolepin pulse. Cells were then washed and incubated for 20 h with
or without cystine (0.09 mM), AT (50 mM), or BSO (0.2 mM), as indicated, at
which time cytolysis was determined. In experiment 1, S.E. averaged 1.2%
for duplicates and spontaneous release was 26%. In experiment 2, S.E.
averaged 1.5% for duplicates and spontaneous release was 22%.
#AT . . 1, aml.notrl.azo e
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cytolysis was dependent upon the presence of cystine. Cytolysis due to
BCNU, observed at substantially higher concentrations (�100 �g/ml), was
not dependent upon the addition of cystine (not shown). Aminotriazole
alone was not toxic, even when present during both the vernolepin pulse
and the 20 h post-vernolepin incubation. Modest enhancement of lysis by
vernolepin was evident if aminotriazole was present during the 20 h
incubation wit� cystine. The combination of aminotriazole and BCNU, as
indicated in the last line of Table X, augmented vernolepin-mediated
cystine-dependent cytolysis to a greater extent than either agent
alone.
Synergy Between BCNU and Vernolepin Plus BSO in the Treatment of
Mice Inoculated with P81S Mastocytoma. Much remains to be learned
concerning the mechanism of action of vernolepin and the role therein
of oxidative injury. Application of our findings to the treatment of
tumor-bearing animals, especially as regards synergy between vernolepin
and inhibitors of antioxidant metabolism, is currently under study. I
will present preliminary results of one such experiment.
In vivo, P81S mastocytoma is a highly metastatic tumor. Dividing
approximately every 20 h, an 8.S-day prolongation of survival as a
result of treatment is equivalent to a 3-log kill of the tumor
inoculum. (C. Nathan, unpublished observations). In the experiment
presented in Table XI, mice were inocluated i.p. with 1 x lOS P81S
cells <)104 the lethal inoculum), followed by injection of the
indicated drugs. Mice treated with vehicle alone died 16-20 days later
(average survival = 18.2 ± 1.S days). BCNU alone had no effect on 3
mice, prolonged the lifetime of 1 mouse by 7 days, and produced 1
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Table XI
Effect of Vernolepin and BSO# With or Without BCNU�
on Survival of Mice Inoculated with P815 Mastocytoma •
•
Treatment
o +
Number n
surviving I
Days to death number injected
16, 17� 19� 19� 20 0/5
17� 19� 19� 25 1 IS
19� 20, 28, 30, 61 0/5
2# 18� 30, 41� 45 0/5
28� 41� 70 2/5
25# 65 3 IS
vernolepin
(mg/kg) BSO BCNU
o
5 +
10 +
2 + +
5 + +
• 5
Five mice per group were inoculated i.p. with 1 x 10 P815 cells in
0.3 ml a-MEM with antibiotics. Within 15 min� vernolepin and BSO (1
mmol/kg)� or vehicle alone, were administered i.p. as a single inject­
ion in 1 ml 0.9� saline, 0.36% DMSO. BCNU (30 mg/kg) was then (within
15 min) administered i.p. in 0.5 ml saline� 2� ethanol, as indicated.
� )90 days
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long-term survivor (>90 days). This dose of BCNU has been shown to
inhibit GR of P81s ascites cells >80� when injected i.p. into mice with
advanced ascites (Nathan and Cohn 1981). Without BCNU, vernolepin (5 or
10 mg/kg) plus BSO did not result in any long-term survivors, though
prolongation of survival was evident for a few mice. The combination of
BCNU with vernolepin plus BSO demonstrated dramatic antitumor activity,
even with as little as 2 mglkg of vernolepin. Additional experiments
are required to establish this point. Furthermore, the role of BSO in
this setting, and the effectiveness of this therapeutic approach for
the treatment of established tumors, must be addressed.
C. Discussion
P81s mastocytoma cells in tissue culture are dependent upon
exogenous cystine for GSH synthesis. Incubation of P81S cells in
cystine-free medium for up to 22 h was not toxic, as judged by trypan
51
blue exclusion or release of Cr label. The effect of cystine-free
medium on cell division or long-term viability was not evaluated.
Presumably, these cells are also dependent upon cystine for protein
synthesis. Three additional murine tumor cell lines in tissue culture
also required extracellular cystine for GSH resynthesis after depletion
by vernolepin (TLX9, P388, and WEHI-164) (not shown). Studying a series
of human lymphoid cell lines from leukemic and normal individuals,
Inglehart et al. (1977) have noted a correlation between cystine
auxotrophy and leukemic origin; lymphoid cell lines from normals did
not require cystine and contained detectable cystathionase activity,
unlike cell lines of leukemic origin. Exploitation of this difference
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by cyst(e)ine depletion therapy has been suggested (Uren et al. 1978;
Uren and Lazarus 1979; Glode et al. 1979).
It was expected that P81S cells incubated in cystine-free medium
would exhibit a level of susceptibility to lysis by a pulse of
vernolepin equivalent to that observed in the presence of BSO in medium
containing cystine. In contrast, and to our great surprise, in the
absence of cystine cells appeared resistant to vernolepin-mediated
lysis. In these experiments, as observed previously, lysis in the
presence of cystine was markedly enhanced by the addition of BSO after
the vernolepin pulse. It should be noted that the vernolepin pulse
itself was in cystine-free medium, and thus cystine need not be present
during vernolepin exposure for cytolysis to occur. In fact, addition of
cystine 8.S h after the vernolepin pulse resulted in significant
cytolysis measured 11.S h later (not shown).
Vernolepin-mediated cytolysis was not dependent upon two other
essential amino acids (leucine or tryptophan) and was not inhibited by
the addition of cycloheximide. Thus, a role for protein synthesis in
the manifestation of toxicity was not evident. It is possible that
the action of some cyst(e)ine-dependent enzyme is required for cell
death resulting from vernolepin exposure.
The hypothesis that cystine-dependent toxicity of vernolepin­
treated cells is the result of intracellular generation of H202 as a
result of cysteine autoxidation arose from two observations. First,
cysteine-associated toxicity to cells in culture, inhibitable by
catalase, has been reported. Second, as demonstrated in Section I of
Results, GSB-depleted P81S cells are very susceptible to lysis by 82°2
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Thus, vernolepin-mediated GSH depletion might sensitize cells to the
oxidant stress associated with intracellular cysteine oxidation. As
noted, however, depletion of GSH may not be the only relevant action of
vernolepin in this setting (Table IX).
Two experimental approaches are suggested by this hypothesis.
First, cytolysis should be dependent upon oxygen. We are just beginning
to learn how to perform the necessary manipulations under conditions of
anoxia. Future experiments will address this question. The second
approach, reminiscent of the work presented in Section I of Results,
involves inhibition of tumor cell antioxidant defenses, beyond the GSH
depletion brought about by vernolepin, as a way of further augmenting
cytolysis. Inhibition of GR with BCNU was found to dramatically enhance
vernolepin-mediated cystine-dependent cytolysis; inhibition of catalase
with aminotriazole demonstrated less synergy (Table X). While these
results are not direct evidence for an oxidative basis of vernolepin
toxicity, they are supportive of the hypothesis.
Intracellular production of H202 via cysteine autoxidation may not
be restricted to vernolepin-treated cells. Thus the susceptibility of
such GSH-deficient cells to oxidative injury may have allowed for the
dramatic manifestation of an aspect of cyst(e)ne metabolism occuring in
untreated cells as well. The potential significance of cysteine as a
source of intracellular oxidant stress should be considered. Avoidance
of such toxicity may be a factor in the maintenance of remarkably low
levels of intracellular cysteine. An analysis of the intra- and extra­
cellular concentrations of free amino acids in BeLa cells grown in
vitro has been provided by Piez and Eagle (1958). Intracellular cystine
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was below the level of detection, specifically (0.05 mM, (the concen­
tration of cystine in the medium was 0.023 mM). Other essential amino
acids were present at higher levels. For instance, intracellular
concentrations of threonine, valine, and histidine were 0.96, 0.79, and
0.26 mM, respectively, representing a 5- to 8-fold increase relative to
extracellular concentrations. Intracellular GSH was present at a
concentration of 4.42 �I. Our hypothesis concerning intracellular
cysteine autoxidation, and the role of antioxidant pathways, is
illustrated in Figure 25.
The rapid mobilization of the cysteine within the GSH molecule for
protein synthesis in rat liver suggests that GSH can function as a
storage form of cysteine (Higashi et al. 1977). thus allowing a cell
quick access to this amino acid without the need to maintain a poten­
tially toxic intracellular pool of the free amino acid. Cellular GSH
can also serve to detoxify the H202 that may be generated by the
cysteine that is present. Thus, as regards the potential for oxygen­
dependent toxicity of intracellular cysteine, GSH metabolism may be of
critical importance.
Other thiols readily autoxidize with the concomitant formation of
H202• For instance, Trotta et al. (1974) have reported that inhibition
of the glutaminase activity of glutamine-dependent carbamyl phosphate
synthetase by dithiothreitol is due to formation of H202• Another thiol
of considerable biological interest, diethyldithiocarbamate (DDC), has
been found to induce the production of H202 when incubated with human
erythrocytes (Sinet et al. 1982), perhaps as a result of oxidation to
the disulfide disulfiram. Disulfiram is taken up by erythrocytes and
Cystine
Rred
)ccystine)CH202�CGSH)lo:::; GRRox Cystei ne 02 H20 GSSG
l Protein synthesis
Glutathione synthesis
etc.
Figure 25. Cysteine autoxidation as a source of intracellular
oxidant stress: a hypothetical scheme.
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reduced to DDe (Stromme 1963). Thus6 a cyclic oxidation-reduction of
disulfiram. as proposed above for cysteine. may be a potent source of
intracellular H202• The relevance of such a mechanism to the inhibitory
activity of disulfiram toward the malaria parasite f. fa1ciparum
(Scheibel et a1. 1979) is suggested by the existence of other
antimalarial drugs which generate an intraerythrocytic oxidant stress.
notably primaquine (Pinder 1973).
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SU�mARY AND DISCUSSION
In response to oxidative injury� murine tumors depend upon the GSB
oxidation-reduction cycle. The susceptibility of tumor cells to lysis
by a flux of B202� such as generated by granulocytes or activated
macrophages in the presence of the secretagogue PMA� or by the enzyme
glucose oxidase� was significantly augmented by interference with the
6SB redox cycle. Various approaches to the inhibition of antioxidant
metabolism of tumor cells were tested (Section I of Results). First�
6SB biosynthesis was inhibited by incubation of cells with BSO� a
selective inhibitor of y-glutamylcysteine synthetase. In the presence
of BSO, cells remained viable and continued to divide, while 6SB
content gradually declined� such that 90% depletion was achieved by 15
h. As an alternative method for GSB depletion, cells were treated with
CDNB, a reactive electrophile and substrate for endogenous 6SB
S-transferase. Sensitization to oxidative cytolysis correlated with
depletion of 6SB by either method by the critera of both dose-response
and the time course of onset and recovery. A third approach involved
inhibition of GR, thereby interrupting the redox cycle. The anti­
neoplastic agent BCNU, an inhibitor of GR at nontoxic doses, was used
in this regard. Bere too, interference in tumor cell 6SB metabolism
enhanced cytolysis by B202• Similar sensitization to oxidative cyto­
lysis as a result of selenium-deprivation-induced deficiency in tumor
cell GPO has been reported by Nathan et al. (1981). In contrast,
inhibition of tumor cell catalase with aminotriazole had no effect on
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susceptibility to lysis by a flux of H202•
In Section II of Results, this theme was extended into another
arena of GSB metabolism, the detoxification of reactive electrophiles
by the formation of thioether conjugates with GSB. The interaction of
tumor cell GSB with four sesquiterpene lactones (SLs), a class of
sulfhydryl-reactive natural products with in vivo antitumor activity in
animal models, was evaluated. SLs are potent depletors of cellular GSB.
Prompt resynthesis of GSB is a critically important component of tumor
cell recovery following exposure to SLs. SL-mediated cytolysis was
dramatically augmented by inhibition of GSB synthesis with BSO. Potent
synergy between BSO and the SL vernolepin was evident even if the two
agents were not present together; inhibition of GSB synthesis by BSO
during or immediately after a I-h exposure to vernolepin resulted in
equivalent cytolysis. For six additional, unrelated antineoplastics,
sulfhydryl reactivity, in terms of their ability to deplete GSB,
correlated with synergistic lysis in the presence of BSO. Cytolysis by
BCNU, however, was not enhanced by BSO, in spite of significant GSB
depletion.
Vernolepin-mediated cytolysis of PSIS cells was dependent upon
exogenous cystine, as was GSB synthesis. This dependence upon cystine
for cytolysis was not due to a requirement for protein synthesis or GSB
synthesis. In view of the tendency of cysteine to autoxidize and
thereby generate B202, it seemed reasonable to suspect that in the
absence of GSB, intracellular cysteine, derived from extracellular
cystine, is a source of H202 sufficient to cause cytolysis. Thus,
vernolepin-mediated cytotoxicity may have a basis in oxidative injury.
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In accord with this hypothesis. inhibition of GR by BCNU significantly
enhanced the toxicity of vernolepin. Inhibition of catalase by amino­
triazole resulted in less dramatic augmentation of vernolepin-mediated
lysis. Future experiments will evaluate the oxygen dependence of
vernolepin toxicity.
Application of these findings to the treatment of tumor-bearing
animals is underway. It is felt that the crucial issues of host
toxicity and therapeutic efficacy are best addressed in the in vivo
setting.
An understanding of the biochemical pathways which function within
the target cell to escape or repair injury can guide the development of
effective anti-microbial therapy as well. Recent findings with the
African trypanosome I. �. brucei illustrate this point. Meshnick et a1.
(1977) have reported an unusually high intracellular H202 concentration
in bloodstream forms of this organism. presumably due to a lack of
catalase. This aspect of trypanosome biochemistry was exploited by the
development of a class of anti-trypanosomal compounds which promote
cleavage of H202 into highly reactive radical species (Meshnick et al.
1977. 1978a). Reasoning that trypanosomes would be more susceptible to
this oxidative damage if their antioxidant defenses were compromised.
they have demonstrated that arsenicals decreased trypanosome GSH
content. increased susceptibility to heme lysis in vitro. and
interacted synergistically with hematoporphyrin D in vivo (Meshnick et
al. 1978b). Indeed. even without exposure to H202-cleaving agents.
these organisms appear to be highly dependent upon their GSB for
protection against the toxicity of self-generated H202• Inhibition of
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GSH synthesis by administration of BSO to infected mice for a length of
time sufficient to result in >95� depletion of trypanosome GSH
(based on the observed half-life of 5 h) resulted in significantly
prolonged survival (2 out of 6 mice were considered cured) (Arrick et
al. 1981).
In summary, the importance of tumor cell GSH metabolism as a
determinant of susceptibility to lysis by H202 or sulfhydryl-reactive
antineoplastic agents has been demonstrated. In addition, these
findings serve to illustrate a potentially useful concept for the
treatment of neoplastic diseases: Elucidation of the critical defense
mechanisms employed by tumor cells in response to therapy could be of
use in the design of synergistic therapeutic combinations, and in the
analysis of drug resistance.
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Table IV
Effect of Cytotoxic SLs on GSH Content of P815 Cells
SL
% GSH
*
J.1g/ml remaining (N)
10 6.7 ± 2.7 (5)
2S 2.8 ± 0.5 (2)
5 41 ± 6.8 (2)
10 23 ± 1.2 (3 )
25 5.7 ± 1.6 (3 )
5 39 ± 2.9 (4)
15 12 ± 0.2 (2)
50 29 ± 3.6 (4)
Vernolepin
Helenalin
Elephantopin
Eriofertopin
*
P815 cells were incubated in a-MEM, 5% horse serum with the
indicated concentrations of sesquiterpene lactones for 1 h.
Data are from 10 experiments with initial GSH = 29.6 nmoll
mg of protein.
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